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1.0 Introduction 
 Atherosclerosis, the disease of large and medium sized arteries is the 
most common disease in western countries and is known to be the underlying 
cause of 50% of all deaths. The prevalence of atherosclerosis is estimated to be 
17 per 1000 (NHIS95), resulting in 1 death per hour among the general 
population of the USA. Atherosclerosis is characterised by the chronic 
accumulation of lipids and fibrous elements in the wall of the blood vessel which 
may result in progressive narrowing of the lumen and consecutive reduction in 
blood flow. The reduced blood flow is the underlying cause of chronic angina 
pectoris and claudication. Atherosclerosis affecting other arteries causes renal 
impairment, hypertension, abdominal aortic aneurysms and critical limb 
ischemia.  On the other hand, rupture of an atherosclerotic plaque may result in 
an acute thrombotic occlusion of a vessel, which may result in myocardial 
infarction, stroke or acute ischemia of the gut or an extremity.  
 
1.1 Pathogenesis of atherosclerosis 
Atherosclerosis is a chronic inflammatory disease which progresses with 
age. The development of atherosclerosis is complex, involving numerous cell 
types and genes. A normal artery is composed of three different layers, 1) the 
inner most layer called tunica intima, composed of a thin layer of collagen and 
proteoglycans covered by a single layer of endothelial cells which line the lumen 
of the artery 2) the middle layer of smooth muscle cells called the tunica media 
and 3) the outer most layer called tunica adventitia which consists of connective 
tissue, fibroblasts and smooth muscle cells (Figure 1).  
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Figure 1: Structure of a normal vessel wall. The cross sectional view shows the three distinct 
layers of the vessel wall: the intima, media and adventitia. (Picture from Lusis AJ, Nature. 2000; 
407(6801):233-41) 
 
 During the initial stages, lipoproteins and their aggregates accumulate in 
the intima of the vessel wall, at sites of lesion predilection. These predilection 
sites are usually the branching points or the inner curvature of the arteries, 
where normal blood flow dynamics are altered1. Subsequently, monocytes and 
lymphocytes adhere to the endothelium, transmigrate across the endothelial 
layer into the intima of the vessel where they proliferate, differentiate and take 
up lipoproteins to form “foam cells”. Though these early plaques or foam cells 
(also termed as ‘fatty streaks’) are not of clinical significance, they are the 
precursors of advanced lesions. As the disease progresses the foam cells die 
and the smooth muscle cells migrate from the medial layer into the intima, 
where they accumulate and proliferate. The so called advanced lesions are 
characterised by the accumulation of smooth muscle cells and dead foam cells, 
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which contribute to the lipid rich “necrotic core”. The smooth muscle cells 
secrete fibrous elements which form the “fibrous cap”, enclosing the lipid rich 
necrotic core. Initially the lesions grow towards the adventitia until a critical point 
is reached after which further growth of the plaques encroaches the lumen. As 
leukocyte recruitment and smooth muscle cell proliferation continues plaque 
development progresses. Additional extracellular matrix production, 
accumulation of extracellular lipid and calcification leads to the development of 
advanced atherosclerotic lesions (Figure 2).  
Depending on the composition, atherosclerotic lesions can be classified 
into two types, namely stable or vulnerable plaques (Figure 2). A “stable plaque” 
has a thick fibrous cap, a small lipid pool, few inflammatory cells and a dense 
extracellular matrix. In contrast, a “vulnerable plaque” is characterised by a thin 
fibrous cap, an increased number of inflammatory cells, a large lipid pool and 
fewer smooth muscle cells. Vulnerable plaques are unstable, which may result 
in plaque rupture and instantaneous occlusion of the vessel. Plaque rupture 
usually occurs at the shoulder of the lesion, resulting in thrombus formation. 
Subsequent embolization of the thrombotic material may lead to additional 
occlusion of distal coronary arteries or cerebral arteries which can further 
aggravate myocardial or cerebral ischemia. 
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Figure 2: Developmental stages of atherosclerosis. (Picture from Hugh Watkins et al., Nature 
Reviews Genetics. 2006; 7: 163-73) 
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1.2 Risk Factors 
Atherosclerosis has a complex aetiology influenced by a number of 
factors. The cardiovascular risk increases with the number of risk factors of a 
patient. Factors which influence atherosclerosis development can be grouped 
into genetic and environmental. In most cases the development of 
atherosclerosis results from complex interactions between environmental and 
genetic factors. 
 
1.2.1 Factors with a strong genetic component 
 
1.      Elevated levels of low density lipoproteins (LDL) 
Low density lipoproteins play an important role in transportation of cholesterol 
and triglycerides from the liver to peripheral tissues and in the regulation of 
cholesterol synthesis. Elevated levels of LDL usually result from mutations in 
the LDL receptor gene, causing familial hypercholesterolemia2. Some of the 
genetic variants which cause elevated LDL levels are the apolipoprotein E3 and 
the apolipoprotein (a) genes4. 
 
2. Reduced levels of high density lipoproteins (HDL) 
High density lipoproteins carry cholesterol from the systemic circulation to the 
liver, where they are excreted or re-utilized. Polymorphisms in the hepatic lipase 
encoding gene and the apolipoprotein AI-CIII-AIV gene cluster results in altered 
levels of HDL5. 
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3. Elevated blood pressure 
Hypertension is considered one of the major cardiovascular risk factors. 
Consequently, treatment of hypertension reduces the risk of cardiovascular 
diseases  by 50%, compared to patients whose blood pressure is uncontrolled6.   
 
4. Elevated levels of homocysteine 
Homocysteine, a sulphur containing amino acid is an intermediate product of 
the metabolism of methionine and cysteine. A single mutation (677C→T) in 
methylenetetrahydrofolate reductase gene causes increased homocysteine 
levels7 associated with premature atherosclerosis.   
 
5. Metabolic syndrome 
Metabolic syndrome is a cluster of metabolic disturbances that strongly 
predisposes to atherosclerosis development8. Peripheral insulin resistance 
seems to be the central phenomenon of the metabolic syndrome, which is 
characterised by impaired glucose tolerance, dyslipidemia, hypertension and 
obesity.  
 
6. Male gender and family history 
It has been reported that below 60 years of age, men develop coronary heart 
disease (CHD) at more than twice the rate of women9.  Individuals with a family 
history, i.e first degree relatives of patients with early onset of cardiovascular 
disease are at a higher risk of developing atherosclerosis which may be due to 
a common genetic predisposition (elevated blood pressure or cholesterol levels) 
or non genetic effects/environmental factors (smoking or diet)10, 11.  
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1.2.2 Environmental factors 
 
      1.  High-fat diet 
High fat and high cholesterol diets have been shown to increase 
atherosclerosis. In experimental models, high fat diets are used to induce 
plaque formation. In humans, regular consumption of high fat diet results in 
obesity and subsequent reduction of average life expectancy. Hence, reduction 
of body weight through diets is one of the main treatment strategies to reduce 
the individual cardiovascular risk. Mediterranean diets rich in olive oil or nuts 
have proved to reduce the cardiovascular risk more effectively than a 
conventional low-fat diet12. Additionally, omega-3 fatty acid rich diets reduce the 
risk of cardiovascular diseases13. 
 
2. Smoking 
It has been calculated that about 30% of cardiovascular deaths are due to 
smoking14. Cigarette smoking increases total cholesterol, triglycerides and LDL-
cholesterin and decreases the cardio-protective HDL-cholesterin. Smoking is an 
established independent risk factor for atherosclerosis development even 
among young individuals15. 
 
3. Infectious disease/chronic inflammatory disease 
Recent studies have shown that inflammation plays a fundamental role in 
development of atherosclerosis16, 17. The signalling cascades that are triggered 
in response to inflammation have a proatherogenic role. Epidemiological and 
basic scientific studies have shown that pathogens like Chlamydia pneumonia18 
 - 9 - 
and Porphyromonas gingivalis19 are associated with atherosclerosis 
development. Chronic inflammatory disease secondary to infection, like 
acquired immunodeficiency syndrome (AIDS) due to infection of human 
immunodeficiency virus (HIV)20 and auto immune diseases like systemic lupus 
erythematosus and rheumatoid arthritis also accelerate atherosclerosis 
development21.  
 
4. Lack of exercise 
Lack of physical exercise and a sedentary life style is an independent risk factor 
for various cardiovascular diseases. Regular exercise results in reduction of 
body fat, LDL cholesterol, triglyceride levels and blood pressure and increases 
atheroprotective HDL cholesterol levels22. Physical exercise is of paramount 
importance as it positively influences many independent cardiovascular disease 
risk factors. 
 
5. Oxidative stress 
Increased levels of oxidants or decreased levels of anti-oxidants secondary to 
dyslipidemia, hypertension, diabetes and smoking are implicated in the 
pathogenesis of atherosclerosis. Oxidation of LDL is considered to be the 
critical step involved in ‘foam cell’ formation23. Oxidation of LDL results in many 
structural modifications and generation of numerous ‘oxidation specific epitopes’ 
such as malondialdehyde (MDA)-lysines and 4-hydroxynonenal (4-HNE)–lysine’ 
which are highly immunogenic. Immunization of mice with MDA and native LDL 
resulted in a significant reduction of atherosclerosis indicating the 
proatherosclerotic role of oxidized LDL (ox-LDL)24.  
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1.3 Oxidative Stress 
 Oxidative stress results from increased production of reactive oxygen 
species (ROS) in biological systems. ROS include “free radicals” and “non-free 
radicals” which are produced during electron transfer reactions in oxygen (O2) 
metabolism. Molecular O2 is essential for the survival of all aerobic organisms 
and acts as the electron acceptor during various metabolic reactions. The 
partially reduced, highly reactive metabolites formed during these reactions 
react more avidly compared to molecular O2. ROS are generally considered to 
be by-products of metabolism with a potential to cause cellular injury25. During 
evolution organisms have developed several strategies to potentially detoxify 
ROS. However, under physiological condition ROS are also important signalling 
molecules26 and there exists a balance between production and detoxification of 
ROS. Diseases may cause an imbalance between the production and 
neutralization of ROS, resulting in altered cell signalling and oxidative stress.  
Superoxide anion formation generates a chain of reactions which result 
in the formation of various highly reactive free radicals and non radicals. In 
atherosclerosis and other vascular diseases ROS are potent pathological 
mediators27, as they cause lipid peroxidation, smooth muscle cell proliferation, 
protein oxidation, inflammatory cell recruitment and vascular inflammation. For 
example, oxidative modification of lipoproteins initiates foam cell formation23 
and vascular oxidative stress is a major cause of cardiovascular diseases28. 
ROS are implicated in the process of initiation of foam cell formation until 
ultimate plaque rupture. Increased oxidative stress results in reduced 
endothelial dysfunction29.  
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1.3.1 Sources of oxidants in the vasculature 
 There are numerous enzymatic sources of ROS in the vasculature, 
including mitochondrial electron transport chain, the arachidonic acid 
metabolizing enzymes lipoxygenase and cyclooxygenase, the cytochrome 
P450s, myeloperoxidase30, xanthine oxidase31, Nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase32, and the nitric oxide synthases 
(NOS).  
 NADPH oxidase and xanthine oxidase are important contributors to 
oxidative stress in cardiovascular diseases32, 33. NADPH oxidase is expressed 
in endothelial cells, smooth muscle cells, fibroblasts and macrophages, while 
xanthine oxidase is expressed in endothelial cells and found in plasma. 
Myeloperoxidase (expressed in neutrophils), the enzyme that converts chloride 
(Cl-) ion to hypochlorous acid, increases atherosclerosis development30, as 
expression of this enzyme was observed in human atherosclerotic lesions. 
Furthermore, footprints of oxidative modifications of LDL by 
myeloperoxidase/HOCl were observed in atherosclerotic lesions34. 
NOS enzymes produce nitric oxide (NO) by their catalytic conversion of 
L-arginine to L-citrulline. This family of enzymes includes the endothelial NOS 
(eNOS or NOS III), inducible NOS (iNOS or NOS II) and neuronal NOS (nNOS 
or NOS I). However, NOS not only produces nitric oxide but may directly 
produce superoxide in special metabolic situations. Under conditions of 
substrate L-arginine or cofactor, (tetrahydrobiopterin (BH4)) deficiency, NOS 
“uncouple” directing electron transfer to molecular oxygen rather than to L-
arginine, resulting in generation of superoxide35-37. In vitro, the generation of 
superoxide and nitric oxide results in the formation of the strong oxidant 
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peroxynitrite38 which by itself causes the formation of a complex array of 
oxidants leading to lipid peroxidation and protein nitration39, 40. Therefore, it has 
been speculated that the superoxide generated by uncoupled NOS might result 
in peroxynitrite formation and consecutive oxidative stress. 
 
1.3.2 Functional role of superoxide in atherosclerosis 
Superoxide functions as a signaling molecule in cell division, 
differentiation and cell survival41, 42. Additionally, increased production of 
superoxide is observed in hypertension, myocardial infarction, diabetes and 
atherosclerosis. Moreover, the severity of atherosclerosis correlates with the 
activation of NADPH oxidase in human carotid arteries43 and NADPH oxidase 
deficient apolipoprotein E knockout (apoE ko) animals showed reduced 
atherosclerosis suggesting an important role of superoxide in atherosclerosis44. 
Increased expression of xanthine oxidase has also been observed in 
atherosclerotic plaques45. 
Superoxide production reduces nitric oxide bioavailability not only by 
direct inactivation of nitric oxide but also by oxidizing the NOS co-factor BH4, 
resulting in NOS “uncoupling”. Reactive oxygen and nitrogen species play a 
central role in the maintenance of vascular homeostasis. Nitric oxide dependent 
cell signaling, including endothelial dependent relaxation, is modulated by both 
superoxide and superoxide dismutase (SOD)46, 47. Alterations in both the rate of 
formation and the extent of superoxide scavenging have been implicated in 
vascular dysfunction, hypertension, diabetes, as well as in chronic nitrate 
tolerance39, 48, 49. The evidence for the involvement of superoxide in impaired 
endothelium dependent relaxations is shown by the restoration of endothelium 
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dependent relaxations using SOD and antioxidants50, 51. Further, deficiency of 
vascular SOD results in impaired endothelial functions47. In addition to reducing 
the bioavailability of nitric oxide, superoxide generation may also promote 
endothelial cell apoptosis52. 
Superoxide generation causes platelet adhesion and aggregation53. 
NADPH oxidase mediated superoxide production causes increased 
leukocyte/endothelial cell interaction in hypercholesterolemic mice54. Further, 
SOD inhibits the expression of vascular cell adhesion molecule-1 (VCAM-1) and 
intercellular cell adhesion molecule-1 (ICAM-1) in endothelial cells55, suggesting 
that superoxide modulates the expression of adhesion molecules. Additionally, 
superoxide promotes vascular smooth muscle cell migration and proliferation52. 
Both superoxide and hydroxyl radical contribute to LDL-oxidation which induces 
cholesterol accumulation in macrophages and leads to foam cell formation56, 57. 
Ox-LDL acts as a chemotactic factor for monocytes and T-cells, the 
predominant population of blood cells found in the atherosclerotic lesions.  
 
1.3.3 Functional role of nitric oxide in atherosclerosis 
Nitric oxide, named the ‘molecule of the year in 1992’ is an important cell 
signaling, effector and vasodilator molecule with potentially strong 
antiatherogenic actions. Of all its functions, it’s role as endothelium dependent 
relaxing factor (EDFR) is the most recognized one, thought to reflect vascular 
homeostasis. Nitric oxide mediates vascular smooth muscle cell relaxation by a 
calcium-ion channel mediated activation of the cyclic guanosine 
monophosphate (cGMP) pathway. Further, nitric oxide inhibits smooth cell 
proliferation, leukocyte/endothelial cell interactions and platelet aggregation. 
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Pharmacological inhibition of nitric oxide production by NOS results in increased 
leukocyte adhesion to microvascular endothelium58 and expression of 
endothelial surface adhesion molecules, including P-selectin and VCAM-159, 60. 
Nitric oxide regulates platelet activation, platelet aggregation and 
platelet/endothelial cell-interactions61-63. It was shown in vitro that nitric oxide 
generated in the coronary and pulmonary vasculature inhibits platelet adhesion 
under constant flow conditions64. By it’s regulation of leukocyte and platelet 
adhesion to the endothelium, nitric oxide contributes to the maintenance of 
microvascular barrier integrity and may decrease local inflammation and 
vascular permeability.  
The eNOS (endothelium) mediated nitric oxide production results in 
vasodilation, increased blood flow and reduced blood pressure. Impairment in 
the endothelial dependent relaxation, termed “endothelial dysfunction” is 
considered to be one of the critical steps in atherosclerosis development. 
Endothelial dysfunction occurs as a result of decreased nitric oxide production, 
decreased sensitivity to nitric oxide or decreased nitric oxide bioavailability65. 
Decreased nitric oxide production may occur secondary to reduced transcription 
or increased instability of eNOS mRNA66. Additionally, altered eNOS activity 
observed in hypercholesterolemia decreases nitric oxide production67, 68. NOS 
inhibitors like asymmetric dimethylarginine (ADMA) and N-monometylarginine 
(NMA) are involved in endothelial dysfunction69.  
The increased production of superoxide observed during condition of 
atherosclerosis decreases the bioavailability of nitric oxide since superoxide 
reacts with nitric oxide at a diffusion limited rate, to form peroxynitrite. The 
reaction rate of superoxide with nitric oxide (6-10x109 M-1sec-1) is faster than the 
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rate at which superoxide is degraded by SOD (2x109 M-1sec-1). Further 
dismutation of superoxide by SOD can occur only if the latter enzyme is present 
in the same compartment in which superoxide is produced. In addition to being 
a significant source of eNOS mediated nitric oxide production, the endothelium 
is also a significant source of superoxide production in atherosclerotic vessels70. 
Since under these conditioms nitric oxide and superoxide are produced in the 
same cellular compartment, i.e., the endothelial cell, they can immediately react 
to form peroxynitrite. Peroxynitrite is a strong oxidant which alters the function 
of biomolecules by protein nitration and lipid peroxidation71 with secondary 
tissue injury39, 40. Subintimal lipoprotein oxidation by peroxynitrite may initiate 
the formation of fatty streaks and subsequent plaque development39. 
Peroxynitrite may also contribute to endothelial cell dependant vascular 
oxidation. 
 
 
 
Figure 3: Proposed functional role of nitric oxide and superoxide in normal and atherogenic 
conditions, respectively. 
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1.4 The nitric oxide pathway in atherosclerosis 
L-arginine, a non-essential amino acid is utilized by the NOS enzyme to 
produce L-citrulline and nitric oxide. The nitric oxide synthesized by all NOS 
may enters one of the following routes: a) activation of soluble guanylate 
cyclase (sGC), which is responsible for most of the physiological effects of nitric 
oxide b) regulation of  expression of adhesion molecules by inducing 
transcription and stabilization of IκBα72, an inhibitor of NF-κB through a cyclic 
guanylate monophosphate (cGMP) independent pathway73 c) reaction with 
oxyhemoglobin to form stable metabolite nitrosylhemoglobin74 d) formation of 
nitrate75 e) formation of peroxynitrite by reacting with superoxide38 f) 
nitrosylation of proteins76, 77. Nitric oxide has no membrane receptor, but binds 
to the heme group of sGC producing a conformational change which increases 
its activity78. sGC converts guanylate triphosphate (GTP) into cGMP which 
activates protein kinase G (PKG), a cGMP dependant protein phosphorylator. 
PKG mediated protein phosphorylation leads to: a) inhibition of L-type calcium 
channels in the plasma membrane79; b) activation of Ca++ ATPase80 and Ca++-
Na+ exchanger in the plasma membrane81; c) activation of Ca++ ATPase at the 
level of the sarcoplasmic reticulum82 and d) inhibition of protein lipase C83. 
Calcium levels have differential roles in the nitric oxide pathway. Intracellular 
free calcium levels in endothelial cells activate NOS by binding to calmodulin84. 
Nitric oxide generated by the activated NOS in the endothelium diffuses into the 
smooth muscle cell layer in the media, where it activates sGC which causes 
feedback inhibition of calcium levels through cGMP mediated mechanisms 
resulting in relaxation of smooth muscle cells in the medial layers of the vessel 
wall. One of the many proteins which are phosphorylated in response to cGMP 
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activation is the vasodilator-stimulated phosphoprotein (VASP). VASP is 
phosphorylated by cGMP dependent PKG which causes the nitric oxide 
mediated inhibition of smooth muscle cell proliferation85. cGMP also down 
regulates the function of some platelet receptors, including the fibrinogen 
receptor IIb/IIIa and P-selectin86.  
The activity of the enzymes involved in the nitric oxide pathway is altered 
during oxidative stress, as observed in atherosclerosis. As mentioned before, 
the expression and activity of eNOS is altered during atherosclerosis. In 
addition the formation of peroxynitrite is capable of impairing the activity of 
sGC87. Atherosclerosis is also associated with low L-arginine availability. 
Subsequently, the altered functional activity of the nitric oxide pathway results in 
vascular smooth muscle contraction and endothelial dysfunction.  
 
1.4.1 Overview of NOS family 
NOS (EC 1.14.13.39) catalyses the conversion of L-arginine to L-
citrulline, yielding nitric oxide as a byproduct. The NOS proteins have ~60% 
amino acid homology and possess similar primary structures. The isoforms are 
expressed in different cellular compartments and function as homodimers, 
composed of two identical monomers. The monomers consist of a C-terminal 
reductase domain and a N-terminal oxygenase domain, which differ in their 
structure and function between isoforms. The synthesis of nitric oxide requires 
L-arginine as a substrate, calmodulin, molecular oxygen and four cofactors: 
flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), 
tetrahydrobiopterin (BH4) and nicotinamide adenine dinucleotide phosphate 
(NADPH). The reductase domain consists of the binding sites for one molecule 
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of NADPH, FAD and FMN, whereas the oxygenase domain binds heme, BH4 
and the substrate L-arginine. As shown in figure 4, between these two domains 
lies the calmodulin binding site, which plays an important role in both structure 
and function of the enzyme.   
The biosynthesis of nitric oxide involves a two step oxidation reaction and 
consumes 1.5 mol of NADPH and 2 mol of oxygen including the formation of the 
intermediate product, NG-hydroxy-L-arginine. The reductase domain transfers 
the electrons from NADPH via the flavins: FAD and FMN to the heme molecule 
in the oxygenase domain, where the substrate L-arginine is oxidized to L-
citrulline and nitric oxide. Hence, the two domains perform catalytically distinct 
functions. Despite the fact that each monomer consists of both domains, 
dimerisation of the enzyme is essential for its catalytic activity since the 
electrons are transferred from the flavins in the reductase domain of one 
subunit to the heme centre in the oxygenase domain of the second subunit88 
(Figure 4). Heme plays a key role in dimerisation of both the subunits in all three 
NOS isoforms and is also required for the interaction between the reductase 
and oxygenase domains.  Calcium dependence is the key feature that 
distinguishes constitutive and inducible isoforms of NOS. eNOS and nNOS are 
activated by elevation of intracellular calcium levels, followed by subsequent 
binding of calcium/ calmodulin. In contrast, iNOS contains irreversibly bound 
calmodulin and thus its activation is independent of intracellular calcium 
concentration.  
Under conditions of either substrate L-arginine or cofactor BH4 
deficiency, all the isoforms of NOS can “uncouple”. The term “uncoupling” 
defines a situation during which the electrons flowing from the reductase 
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domain to the oxygenase domain are shifted to molecular oxygen instead of L-
arginine, resulting in superoxide rather than nitric oxide production. However, 
the conditions and mechanisms that cause uncoupling differ between the NOS 
isoforms. Furthermore, NOS isoforms vary in their regulation of gene 
expression, catalytic activity and the cellular compartment of gene expression. 
These features make each isoform unique and give rise to distinct mechanistic 
features that are responsible for their differential function under various 
physiological and pathophysiological conditions. 
 
 
Figure 4: Structure of functional NOS dimers. Electrons in the NOS dimer flow via 
NADPH→FAD→FMN in the reductase domain (shaded region) of one monomer to the heme 
(Fe) in the oxygenase domain of the second monomer. Calmodulin (CaM) binding is essential 
for dimerisation of the enzyme. Dimerisation of NOS is required for conversion of L-arginine to 
L-citrulline and nitric oxide. (Picture adapted from Andrew PJ et al., Cardiovascular Research. 1999; 43: 
521-31) 
 
1.4.2 Unique features of NOS isoforms 
The functional relevance of nitric oxide generated by each NOS isoform 
differs depending on the cellular compartment and the target proteins 
expressed in the compartment. Because of the versatile properties of nitric 
oxide, the expression, activity, spatial distribution and proximity of NOS 
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isoforms to the regulatory and target proteins are tightly regulated and vary 
between the isoforms. 
 
 
 
 
Figure 5: Distinct domain structure of each NOS isoform. Binding sites for L-arginine (Arg), 
heme, tetrahydrobiopterin (BH4), calmodulin (CaM), flavins (FAD and FMN) and NADPH are 
indicated. The oxygenase, reductase and PDZ (nNOS) domains are indicated by solid bars. The 
numbers indicate the amino acid residues within in each domain. Myristoylation (Myr) and 
palmitoylation (Palm) sites on eNOS are shown. The irreversible binding of calcium to the 
calmodulin in iNOS is indicated. (Picture adapted from Alderton WK et al., Biochem J. 2001; 357: 
593-615) 
 
1.4.2.1 Endothelial nitric oxide synthase (eNOS) 
eNOS is the main source of endothelial nitric oxide production in the 
vasculature. As mentioned in detail before, nitric oxide generated by eNOS 
plays an important role in the prevention of leukocyte/endothelial interactions 
and smooth muscle cell proliferation. In addition to the endothelium, eNOS is 
also expressed in cardiomyocytes and cardiac conduction tissue. eNOS 
belongs to the constitutively expressed, calcium dependant  NOS isoforms. 
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Several physiological situations like shear stress and exercise training increase 
eNOS expression89. Transforming growth factor-β (TGF-β) and tumor necrosis 
factor-α (TNF-α) influence eNOS mRNA levels. While TGF-β induces eNOS 
mRNA and protein expression as well as enzyme activity 90, TNF-α down 
regulates eNOS expression91. 
The activity of eNOS is regulated by a number of mechanisms including 
post translational modification, mediating sub cellular localization of the 
enzyme92, 93. Hormones like estrogen, catecholamines, vasopressin and platelet 
derived mediators such as serotonins increase eNOS function. The activity of 
eNOS is also determined by signaling complexes which are composed of the 
enzyme and a conglomerate of adaptor proteins, structural proteins, kinases, 
phosphatases and potentially proteins which affect association and determine 
intracellular localization. The kinases and phosphatases phosphorylate and 
dephosphorylate eNOS at various sites resulting in activation or attenuation of 
the enzyme. For example, eNOS phosphorylation at Ser1177 activates eNOS 
whereas phosphorylation at Thr495 attenuates eNOS activity. It was shown that 
protein kinase C (PKC) promotes both the dephosphorylation of Ser1177 and 
the phosphorylation at Thr495, resulting in attenuated enzymatic activity94. In 
contrast cAMP dependent protein kinase (PKA) signaling leads to eNOS 
phosphorylation at Ser1177 and dephosphorylation at Thr495 resulting in 
activation of the enzyme94.  In addition to the modulation by phosphorylation, 
protein-protein interactions also influence eNOS activity. Further, post 
translational modifications like N-terminal acylation, specifically myristoylation 
and palmitoylation determines the sub cellular localization of the enzyme. The  
modification targets eNOS to both the plasmalemmal vesicles, caveolae and the 
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perinuclear/golgi region within the cell95, 96.  Within the caveolae, eNOS is bound 
to caveolin-1 in its inactive form97. Calcium influx disrupts the caveolin-1/eNOS 
complex and results in eNOS activation98. Additionally, dynamin-2 and Hsp-90 
interact with eNOS and positively regulate the enzyme’s activity99, 100.  
Superoxide production by eNOS “uncoupling” is believed to result from 
BH4 deficiency rather than L-arginine deficiency101. The amount of superoxide 
generated by eNOS depends on calcium/calmodulin binding. In the absence of 
calcium/calmodulin, eNOS generates low amounts of superoxide and the 
activation by calcium/calmodulin increases superoxide production102.  Heme 
blockers like cyanide or imidazole prevent eNOS mediated superoxide 
generation during BH4 deficiency. This suggests that eNOS generates 
superoxide from the heme containing oxygenase domain35. One possible 
mechanism by which BH4 deficiency  occurs is BH4 oxidation103.  
 
1.4.2.2 Neuronal nitric oxide synthase (nNOS) 
nNOS is involved in a wide variety of physiological and pathological 
processes, including neurotransmission, neurotoxicity, skeletal muscle 
contraction, body fluid homeostasis and cardiac function104. Though the name 
implies the expression of this isoform in neuronal tissues, nNOS is expressed in 
epithelial cells, mesanglial cells, skeletal muscle cells and cardiomyocytes. In 
the vasculature, nNOS is expressed in endothelial105 as well as smooth muscle 
cells of rat and human origin106. nNOS is the largest of the NOS isoforms 
containing an additional 300 amino acids at the N-terminus. This domain is 
called the PDZ (PSD-95 discs large/ zona occludens -1 homology domain) 
domain or disc-large homologous region (DHR), which is essential for nNOS 
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binding to other proteins and sub cellular localization. In neurons, nNOS is 
associated with the rough endoplasmic reticulum and the synaptic 
membrane107, 108 whereas in skeletal muscle, nNOS localizes to the 
sarcolemma109.  Some studies have also shown the localization of nNOS 
protein in the cytosol110-112. The localization of nNOS differs depending on the 
cellular compartment or the pathophysiological conditions.  
The gene structure and the expressional regulation of nNOS are highly 
complex. The expression of nNOS is tightly regulated by post-transcriptional 
and post-translational mechanisms. Several nNOS mRNA species are 
expressed in different tissues in a developmentally regulated manner. Post-
transcriptional regulation of nNOS involves multiple promoter usage, alternate 
splicing through deletion and insertion of exons, varied sites for 3’ untranslated 
region cleavage and polyadenylation. The alternative splicing results in the 
generation of nNOS proteins which differ in their structural features and catalytic 
activity. The full length nNOS protein, nNOS-α has high catalytic activity and is 
coded by multiple transcripts113. Two additional splice variants of nNOS, the 
nNOS-β and nNOS-γ  lack the PDZ domain. The nNOS-β and the nNOS-γ 
variants have about 80% and 30% of the catalytic activity of full length nNOS-α, 
respectively.  Because of the lack of the PDZ domain, which is responsible for 
targeting nNOS to synaptic membranes, nNOS-β is localized to the cytosol114. 
Another splice variant, nNOS-µ possesses an in-frame insertion of 34 amino 
acids between the oxygenase and the reductase domains and has similar 
catalytic activity compared to nNOS-α115. Alternative splice variants of nNOS 
differ in their cellular compartment of expression and serve differential roles 
under physiological and pathological conditions.  
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 nNOS interacts with several proteins which determine the targeting of 
the enzyme or the enzymatic activity. Targeting of nNOS to appropriate sites in 
the cell is mediated by its PDZ domain. Some of the proteins that bind to the 
PDZ domain and are essential for nNOS targeting are CAPON (carboxy-
terminal PDZ ligand of nNOS), NIDD (nNOS interacting DHHC domain), 
dystrophin family of proteins and post-synaptic density proteins (PSD) 93 and 
95100. Proteins which negatively regulate nNOS activity are protein inhibitor of 
nNOS (PIN), nitric oxide synthase-interacting protein (NOSIP) and caveolin-
3100. nNOS is also translationally regulated by phosphorylation through 
calmodulin-dependent kinases. Phosphorylation of nNOS by calmodulin-
dependent kinase II resulted in a decrease in the enzyme activity whereas 
phosphorylation by PKC caused a marked increase in enzyme activity116. 
Of all the three isoforms of NOS, nNOS was the first enzyme which was 
shown to “uncouple”, to produce superoxide instead of nitric oxide36. In the 
absence of its substrate L-arginine, nNOS catalyses the generation of 
superoxide from the oxygenase domain117. In the presence of L-arginine nNOS 
can generate nitric oxide and superoxide. The ratio of the two radicals depends 
on the concentration of the substrate, BH4117, 118. Similar to eNOS, BH4 inhibited 
superoxide production from nNOS in a dose dependent manner. Interestingly, 
L-arginine alone, independent of the dose of BH4 inhibited superoxide 
production, suggesting that substrate deficiency but not BH4 deficiency 
determines the superoxide production by nNOS118. Recently studies have 
shown that the methyl arginines, asymmetric dimethyl arginine (ADMA) and NG-
monomethyl L-arginine modulate superoxide as well as nitric oxide generation 
from nNOS. Further this study shows that even in the presence of normal 
 - 25 - 
substrate and co-factor concentration nNOS generates superoxide119. In 
addition to superoxide nNOS is capable of generating of hydrogen peroxide 
(H2O2) in the absence of substrate, using molecular oxygen as the terminal 
electron acceptor120. In this reaction, BH4 plays a critical role in regulating the 
generation of superoxide and hydrogen peroxide121. In terms of enzymatic 
activity during uncoupling, nNOS differs from other NOS isoforms in its 
readiness to catalyze the uncoupled reaction i.e., nNOS oxidizes NADPH at a 
higher rate than the other NOS isoforms122. Supporting this concept, in the 
absence of substrate, nNOS produces higher amounts of superoxide than  
iNOS123. 
 
1.4.2.3 Inducible nitric oxide synthase (iNOS) 
Unlike eNOS and nNOS which are constitutively expressed, iNOS is 
expressed only when induced by external stimuli. Nitric oxide generated by 
iNOS mediates the cytotoxic actions of activated macrophages and neutrophils 
and plays an important role in the non specific immune response of the 
pathogenic defense mechanism. iNOS is expressed in many nucleated cells of 
the cardiovascular system namely vascular smooth muscle cells, endothelial 
cells, cardiac myocytes, inflammatory cells found in sub endothelial space such 
as leukocytes, fibroblasts and mast cells during various diseased conditions. In 
contrast to eNOS and nNOS which are regulated by intracellular calcium levels, 
iNOS contains irreversibly bound calmodulin and hence is independent of 
intracellular calcium levels. Thus, induction of iNOS results in generation of 
tremendous levels of nitric oxide124.  
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iNOS expression is regulated transcriptionally following cytokine (tumor 
necrosis factor-α, interleukin-1β, interleukin-2 or interferon gamma-γ) or 
bacterial lipopolysaccharide stimulation. Additionally, post transcriptional 
regulation is implicated. The 3’ untranslated region of iNOS possess an 
‘AUUUA’ motif which potentially destabilizes iNOS mRNA125. LPS and IFN-γ 
increase mRNA stability while transforming growth factor-β (TGR-β) decreases 
the translation of iNOS mRNA without affecting its rate of transcription and also 
increases iNOS protein degradation and activity126, 127. Alternative splice 
variants of iNOS have been detected in human cells, which lack the heme 
domain (denoted iNOS8-9-) or in the FMN binding region128. iNOS8-9- is 
functionally inactive as it is unable to form homodimers129. Additionally, two 
splice variants of iNOS were identified in normal lymphocytes and chronic 
lymphocytic leukemia cells130 which regulate nitric oxide production in these 
cells. Further regulation of iNOS enzyme activity is achieved by 
phosphorylation131 and binding of iNOS protein to caveolin-1 which results in an 
increased protein degradation132. Though iNOS does not contain specific 
membrane targeting sequences, it is found to be membrane associated in 
neutrophils and macrophages133, 134 and localizes to both cytosol and 
peroxisomes in hepatocytes135. 
In contrast to eNOS and nNOS “uncoupling” of iNOS occurs in the 
presence of high concentration of L-arginine (5 mM)136. While 100 µM of L-
arginine completely blocks superoxide generation from nNOS, it did not block 
superoxide generation by iNOS. Even in the presence of 1 mM L-arginine the 
superoxide production by iNOS was only partially blocked suggesting that iNOS 
is capable of generating superoxide even when the availability of L-arginine is 
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adequate136.  While eNOS and nNOS generate superoxide from their 
oxygenase domains, iNOS catalyses the production of superoxide from its 
reductase domain136.  Therefore, iNOS was proposed to simultaneously 
generate nitric oxide from L-arginine bound to its oxygenase domain, while 
generating superoxide from its reductase domain (Figure 6). This simultaneous 
generation of superoxide and nitric oxide results in iNOS mediated peroxynitrite 
generation, a more potent oxidant than superoxide which enhances the anti 
microbial activity of iNOS37. 
 
 
 
Figure 6: Schematic diagram depicting superoxide generation of iNOS from its reductase 
domain. Solid arrows indicate electron flow. In the presence of L-arginine simultaneous 
generation of superoxide and nitric oxide may occur at the reductase and oxygenase domains 
respectively. (Picture from Xia Y et al., J Biol Chem. 1998; 273: 22635-39). 
 
1.5 The apoE ko model of atherosclerosis 
Experimental investigation of the mechanisms and progression of 
atherosclerosis have been greatly facilitated by the use of mouse models. The 
advent of gene targeting allowed the generation of mice which lack the gene for 
apoE137. These apoE ko mice serve as a practical atherosclerosis model since 
they spontaneously develop complex atherosclerotic lesions closely resembling 
human disease. ApoE is an important component of the reverse cholesterol 
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transport pathway and is an essential ligand for the uptake and clearance of 
atherogenic lipoproteins138. ApoE is a constituent of chylomicrons, very low 
density lipoproteins (VLDL) and HDL. Genetic deletion of apoE in mice, a 
species normally resistant to atherosclerosis, is associated with 4-5 times 
increased plasma cholesterol levels. Although the pathomechanism of 
atherosclerosis development differs from common human disease, the apoE ko 
model has substantially shaped our understanding of the role of apoE in lipid 
transport and proved to be a valid atherosclerosis model139.  
 
1.6 Role of NOS isoforms in cardiovascular diseases 
1.6.1 Role of eNOS in cardiovascular diseases 
Endothelium derived nitric oxide plays a major role in modulating several 
cardiovascular functions140. Nitric oxide generated by eNOS serves as an 
endothelium derived relaxing factor, regulates vascular tone and blood 
pressure. Furthermore, it exerts potential anti atherosclerotic effects as it 
inhibits vascular smooth muscle cell proliferation, platelet aggregation and 
leukocyte adhesion140,141.  The importance of endothelium derived nitric oxide in 
maintaining normal endothelial function has been described in detail in section 
(1.3.3). Reduced bioavailability of nitric oxide has been associated with several 
cardiovascular diseases. One of the potential mechanisms leading to reduced 
nitric oxide bioavailability is the uncoupling of eNOS. Uncoupling of eNOS is 
observed in several cardiovascular diseases but may also serve as an 
important defense mechanism of the normal endothelium142. Furthermore, 
alteration in the sub cellular localization of eNOS resulting in decreased activity 
of the enzyme has been observed during various disease conditions143.  
 - 29 - 
Multiple lines of evidence point to an important cardioprotective effect of 
eNOS. For example, eNOS deficiency resulted in neoinitima proliferation in a 
vascular injury model144 and over expression of eNOS decreased neointimal 
and medial thickening, decreased leukocyte infiltration, reduced intracellular 
adhesion molecule (ICAM-1) and vascular cellular adhesion molecule (VCAM-1) 
expression, in a carotid artery ligation model of vascular remodelling145. eNOS 
protects from myocardial dysfunction. Targeted over expression of eNOS within 
the vascular endothelium in mice attenuates cardiac and pulmonary dysfunction 
and dramatically improved survival in congestive heart failure146. The same 
authors have reported that over expression of eNOS results in attenuation of 
myocardial infarction size147. 
Atherosclerosis is associated with endothelial dysfunction, decreased 
eNOS activity and reduced cGMP levels67. Genetic deletion of eNOS resulted in 
increased arteriosclerosis in an aortic transplant model suggesting that eNOS 
protects from transplant arteriosclerosis148. We and others have shown that 
deletion of eNOS resulted in acceleration of plaque formation in apoE ko 
mice149, 150. Additionally, the apoE/eNOS dko mice developed vascular 
complications like abdominal aortic aneurysms, aortic dissections, distal 
coronary artery disease, as observed in human atherosclerosis149. Secondary to 
eNOS deletion, apoE/eNOS dko mice were hypertensive and showed impaired 
left ventricle function and cardiac hypertrophy, possibly a result of chronic 
myocardial ischemia, resulting from coronary artery disease149. However, eNOS 
may also increase atherosclerosis development as recently, over expression of 
eNOS accelerated atherosclerosis151. As a potential mechanism, uncoupling of 
eNOS  with resultant superoxide production was observed in this model. 
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Interestingly, BH4 supplementation resulted in decreased atherosclerosis, 
decreased superoxide and increased nitric oxide in this transgenic mice. Taken 
together, all these studies show that the presence of a functionally active eNOS 
is essential for the prevention of atherosclerosis.  
 
1.6.2 Role of nNOS in cardiovascular diseases 
 Nitric oxide generated by nNOS functions as a non-adrenergic non-
cholinergic neurotransmitter in the autonomous nervous system. Non-
adrenergic non-cholinergic perivascular nerves (nitrergic nerves) found in the 
adventitia of cerebral and certain peripheral arteries (e.g. mesenteric, renal and 
femoral arteries) contain nNOS. In perivascular nitrergic nerves, nNOS derived 
nitric oxide causes relaxation of adjacent vascular smooth muscle cells, 
counterbalancing vasoconstriction mediated by the sympathetic nervous 
system152. nNOS expressed in cardiomyocytes plays an important role in 
regulating cardiac function153. In this respect, deletion of nNOS resulted in a 
higher heart rate and decreased heart rate variance compared to wildtype 
mice154. Genetic deficiency of nNOS resulted in increased myocardial infarction 
size and increased superoxide formation suggesting that nNOS serves a 
protective role in myocardial injury155. Following myocardial reperfusion injury, 
lack of nNOS resulted in a significant increase in cardiac polymorphonuclear 
leukocyte infiltration156. 
Recent studies have shown the expression of nNOS in normal vascular 
smooth muscle cells of carotid157, coronary158 and pulmonary159 arteries and the 
aorta160. In the absence of functional eNOS under pathophysiological 
conditions, nNOS may regulate normal vascular tone160. Further, studies have 
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shown that nNOS inhibits leukocyte/endothelial cell interactions in the 
cremasteric microcirculation of mice,  in the absence of eNOS161.  In a mouse 
carotid artery ligation model, nNOS derived nitric oxide suppresses both 
neointimal formation and constrictive vascular remodelling162. In the same study 
the authors have shown that nNOS exerts an important inhibitory effect on 
vasoconstrictor response following balloon injury. Though there was no 
expression of nNOS before vascular injury, nNOS was up regulated in the 
neointima and medial smooth muscle cells after carotid artery ligation and 
balloon injury, suggesting a vasoprotective effect of nNOS in response to injury. 
Gene transfer of nNOS in venous bypass grafts resulted in substantial reduction 
of adhesion molecule expression and inflammatory cell infiltration in early 
venous bypass grafts (3 days after operation)163. In late venous bypass grafts 
(28 days after operation), nNOS gene transfer resulted in reduction of smooth 
muscle cell hyperplasia and reduced vascular superoxide production163. 
nNOS is detected in endothelial cells and macrophages in both early and 
advanced atherosclerotic lesions in humans, while it is absent in normal 
vessels164. nNOS is also expressed in the carotid artery of spontaneously 
hypertensive rats157 and in the aorta of apoE ko165 and apoE/iNOS double 
knockout (dko) mice166. Because nNOS is induced in various vascular 
pathologies like atherosclerosis, vascular injury and hypertension, nNOS should 
not be considered a “constitutive” enzyme. Rather, nNOS is subject to 
expressional regulation in the vascular system, while it is constitutively 
expressed in the nervous system167. We have recently shown that genetic 
deletion of nNOS resulted in accelerated atherosclerosis in apoE ko mice165, 
suggesting that nNOS is atheroprotective. We also showed that nNOS improves 
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the survival rate, as apoE/nNOS dko mice had a 30% increased mortality 
compared to apoE ko controls. However, the exact mechanism by which nNOS 
acts as an anti-atherosclerotic enzyme is still not clear. It was speculated that 
nNOS localized towards to the lumen of the vessel might decrease leukocyte 
and platelet adhesion while nNOS expressed in the adventitia might inhibit 
smooth muscle cell proliferation168.  Since nNOS also uncouples under 
conditions of substrate deficiency, the role of nNOS derived superoxide and 
nitric oxide in the formation of atherosclerosis still has to be defined.  
 
1.6.3 Role of iNOS in cardiovascular diseases 
Under normal physiological conditions, iNOS is unlikely to have any 
functional role in the cardiovascular system due to its low (or absent) 
expression. However, a large number of reports are available which provide 
evidence for the expression of iNOS under pathophysiological conditions, both 
in humans as well as in animal models. In this respect, iNOS expression is 
detected in atherosclerosis, following balloon injury and restenosis, in 
cardiomyopathy, sepsis, transplant rejection and a variety of disorders 
associated with acute and chronic inflammation. Under normal physiological 
conditions iNOS expression has important anti microbial and anti tumor 
activities since it is capable of generating high cytotoxic concentration of nitric 
oxide. In chronic inflammation, however, the production of high cytotoxic nitric 
oxide and superoxide production by the enzyme may become detrimental. LPS 
injection was shown to increase leukocyte rolling and adhesion to post capillary 
venules of iNOS knockout (iNOS ko) mice suggesting that iNOS induction can 
act as a negative regulator of leukocyte trafficking in the microcirculation169. 
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Transient gene transfer mediated expression of iNOS decreases smooth 
muscle cell proliferation and prevents neointima formation following balloon 
angioplasty in rats and pigs170. The same authors reported that iNOS gene 
transfer protects aortic allografts from developing allograft arteriosclerosis171. In 
mice, iNOS protects from developing transplant arteriosclerosis by inhibiting 
neointimal smooth muscle accumulation172. Another recent study showed that 
iNOS prevents vein graft arteriosclerosis by inhibiting vascular smooth muscle 
cell proliferation173 and neointimal hyperplasia174. 
In vitro, iNOS ko mice show an improved cardiac reserve following 
myocardial infarction which was thought to be necessary to the reduction in 
oxidative stress seen in this model175.  Genetic deletion of iNOS gene also led 
to partial protection against acute cardiac mechanical dysfunction mediated by 
pro-inflammatory cytokines176. The expression of iNOS is considered to be 
responsible for impairment of eNOS derived nitric oxide production in vessels 
treated with inflammatory mediators177. Further studies suggest that iNOS plays 
an important role in the impairment of endothelium dependent vascular 
relaxation, which may occur in part by limiting cofactor availability (BH4) and 
subsequent eNOS uncoupling178. The expression of iNOS by macrophages and 
smooth muscle cells in atherosclerotic lesions has been taken as evidence for 
its detrimental role in atherosclerosis, due to formation of peroxynitrite179. We 
and others have shown that genetic deletion of iNOS resulted in a significant 
reduction of lesion formation in apoE ko mice, documenting the proatherogenic 
potential of iNOS180, 181. Our results were reconfirmed by Hayashi et al. who 
showed that selective pharmacological inhibition of iNOS results in retardation 
of atherosclerosis in rabbits182.  
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The seemingly opposing effects of iNOS under various pathological 
conditions may be due to differences in the cellular compartment of iNOS 
expression in cardiac muscle vs. vessel wall; chronic atherosclerosis vs. 
transplant arteriosclerosis or smooth muscle cell proliferation following balloon 
angioplasty. iNOS expression relevant to atherosclerosis development was 
detected in vascular smooth muscle cells, mononuclear cells and lymphocytes. 
These various cellular sources are capable of generating different amounts of 
iNOS and subsequently target iNOS expression to various compartments of the 
plaque. Moreover, the cellular source determines a specific array of genes co-
expressed with iNOS, which may influence their redox status183. For example, 
leukocytes can produce substantial amounts of nitric oxide and superoxide from 
iNOS and NADPH oxidase, resulting in the formation of peroxynitrite184. 
Peroxynitrite can oxidize LDL and cause nitrosylation of proteins which 
influences protein function71. Moreover, under conditions of substrate (L-
arginine) or cofactor (BH4) deficiency NOS can “uncouple” to generate 
superoxide  instead of nitric oxide136. Even more intriguing, iNOS is likely 
capable of producing nitric oxide and superoxide simultaneously which could 
directly lead to peroxynitrite formation37. Whether iNOS is “uncoupled” in 
atherosclerosis and produces substantial amounts of superoxide in addition to 
nitric oxide is currently unknown. 
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1.7 Aim of the study 
As described in the previous section, NOS isoforms differ in their 
physiological regulation, cellular compartment of expression, sub cellular 
localization and catalytic activity suggesting a complex involvement in 
atherosclerosis development. Therefore, it is a considerable challenge to 
discern the role of each NOS isoform in atherosclerosis development, as all 
three NOS isoforms are expressed in the vessel wall. Unfortunately, the use of 
pharmacologic NOS inhibitors is limited by their inability to selectively and fully 
inhibit each NOS isoform. In contrast, gene knockout models allow the 
dissection of the distinct roles of each NOS isoform in vascular disease. In the 
past, we crossed eNOS ko, nNOS ko and iNOS ko mice with atherosclerotic 
apoE ko mice, generating apoE/eNOS dko, apoE/nNOS dko and apoE/iNOS 
dko mice respectively, to test the contribution of each NOS isoform in diet 
induced atherosclerosis.  
Our previous experiments revealed that eNOS149 and nNOS165 are anti 
atherosclerotic as genetic deletion of these enzymes resulted in accelerated 
atherosclerosis in apoE ko mice. In contrast, genetic deletion of iNOS resulted 
in a significant reduction of lesion formation suggesting that iNOS is 
proatherogenic180. The contribution of the NOS isoform with regards to local 
superoxide and nitric oxide in atherosclerosis is currently unknown. However, 
detailed information about the radical production by each NOS isoform is of key 
importance to understand the pathomechanism involved in NOS mediated 
modulation of atherosclerosis development.  
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The purpose of the study presented here was: 
1. Establishment and validation of Electron Spin Resonance (ESR) 
measurements of nitric oxide from vessel rings using a bench top Bruker, 
e-scan spectroscope.   
2. Establishment and validation of ESR measurements of superoxide from 
the vessel rings. 
3. Quantitation of the relative contribution of each NOS isoform to the total 
nitric oxide levels observed in atherosclerotic vessel and bioavailable 
nitrosyl hemoglobin (No-Hb) in the circulation.  
4. Determination of superoxide production by each NOS isoform in the 
atherosclerotic vessel wall. 
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2.0 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Mice 
Mice were backcrossed for 10 generations to the C57Bl6 genetic 
background. eNOS ko185 and nNOS ko186, provided by Paul Huang, and apoE 
ko (Jackson Laboratories, Bar Harbor, ME, USA) were crossed to generate 
double heterozygous mice. Similarly, iNOS ko mice obtained from (Jackson 
Laboratories, Bar Harbor, ME, USA) were crossed with apoE ko mice to 
generate double heterozygous mice. Offsprings were crossed and the 
progenies were genotyped for eNOS and nNOS by southern blotting and for 
apoE and iNOS by polymerase chain reaction. apoE ko, apoE/eNOS dko, 
apoE/iNOS dko, apoE/nNOS dko animals were weaned at 21 days and fed a 
western-type diet (42% of total calories from fat; 0.15% cholesterol; Harlan 
Teklad, USA) for 18-20 weeks. C57Bl6 mice were obtained from Charles Rivers 
Laboratories (Germany). The animals were maintained at 12 hours light-dark 
cycle.  
 
2.1.2 Chemicals and reagents 
Reagents                                                        Source          
For Krebs Hepes Buffer (KHB) 
Calcium chloride dihydrate   Sigma    
Sodium chloride     Sigma    
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Magnesium sulphate, heptahydrate  Sigma    
Potassium chloride     Sigma    
Sodium bicarbonate    Sigma    
Potassium dihydrogen phosphate  Sigma         
D(+)Glucose      Sigma    
Hepes      Sigma    
 
Reagents                                                        Source          
For Electron Spin Resonance (ESR) 
Iron (II) sulphate heptahydrate   Sigma            
Diethyldithiocarbamic acid. Sodium salt 
. trihydrate (DETC)     Alexis       
1-hydroxy-3-methoxycarbonyl- 
2,2,5,5-tetramethylpyrrolidine (CMH)  Noxygen           
3-carboxyl-2,2,5,5-tetramethyl- 
1-pyrrolidinyloxy (CP)    Noxygen           
Deferoxamine mesylate salt   Sigma            
 
For High Performance Liquid Chromatography (HPLC) 
HPLC water      AppliChem   
Acetonitrile      Sigma    
Trifluoroacetic acid     Sigma    
Dihydroethidium     Molecular Probes   
Methanol      J.T.Baker   
 
 - 40 - 
Reagents       Source      
For Immunohistochemistry 
Acetone      J.T.Baker    
Hydrogen peroxide     Sigma     
Blocking solution     Dako     
ABC reagent      Vector Laboratorties  
DAB reagent      Vector Laboratorties  
 
For Mayer’s Haemalaun stain   
Haematoxylin     Roth     
Sodium iodate     Merck     
Aluminium calcium sulphate   Merck     
Chloral hydrate     Merck     
Citric acid      Merck     
 
Antibodies 
Anti nitrotyrosine antibody    Upstate    
Anti rabbit IgG     Vector Laboratories   
 
Buffers and Solutions 
Krebs Hepes Buffer (KHB) 
KHB with the following composition, prepared in Milli Q water, was used for the 
experiments 
Sodium chloride     99 mM 
 Potassium chloride      4.69 mM 
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 Calcium chloride     2.5 mM 
 Magnesium sulphate    1.20 mM 
Sodium bicarbonate    25 mM 
Potassium dihydrogen phosphate   1.03 mM 
D (+) Glucose     5.6 mM 
Sodium Hepes     20 mM  
 
The above reagents were dissolved in 500 ml of MilliQ water. The pH 
was adjusted to 7.4. The pH was checked every day before use and the buffer 
was filtered using a 0.22 µm filter (Schleicher&Schuell). 
 
Phosphate Buffered Saline (PBS) 
9.55 g of PBS were dissolved in 1 litre of distilled water to obtain a 
working solution of PBS. 
 
Mayer’s Haemalaun stain   
Haematoxylin     6 g     
Sodium iodate     1 g 
Aluminium calcium sulphate   250 g 
Chloral hydrate     250 g     
Citric acid      5 g 
All these reagents were dissolved in 5 liters of distilled water. 
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Others 
Reagents                                                  Source          
Pegulated Superoxide Dismutase  
(PEG-SOD)       Sigma    
Apocynin          Sigma    
Phosphate buffered saline    Biochrom AG   
Sodium Hydroxide        Merck     
BCA protein assay kit    Pierce     
Nitric oxide synthase inhibitors 
L-arginine methyl ester hydrochloride 
(L-NAME)      Sigma     
L-NIO       Alexis     
N-(3-aminomethyl) benzyl-acetamidine 
(1400W)      Alexis     
N-[(4S)-4-amino-5-[(2-aminoethyl) 
amino] pentyl]-N'-nitroguanidine tris 
(trifluoroacetate) salt  (N-AANG)   Sigma     
 
Instruments and Accessories 
Stereosome microscope    Leica 
e-scan ESR spectroscope    Bruker BioSpin GmbH 
Akta HPLC      Amersham Biosciences 
Fluorescence Detector    Jasko 
Image Pro-Plus software    Media Cybernetics   
Elisa reader      Softmax (Molecular Devices) 
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Spectrophotometer     Pharmacia Biotech 
Cold plate      Noxygen 
12 well and 96 well plates    Falcon 
Incubator      WTC Binder 
pH meter      InoLab 
Centrifuge      Eppendorf 
Water Bath      Thermomix 
Homogenisers     Roth 
0.22 µm Filters     Schleicher&Schuell       
0.22 µm 13mm-PTFE Filters   Millipore 
Tissue Tek      Sakura Finetek 
 
2.1.3 Preparation of reagents  
KHB was filtered using a 0.22 µm filter and the pH was checked daily. 
KHB solution containing 25 µM Deferoxamine and 5 µM DETC was used to 
prepare the spin probe, 1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine (CMH). The solutions were prepared fresh just before 
use. Filtered 0.9% NaCl was used to prepare 1.6 mM FeSO4 and 3.2 mM DETC 
solutions for nitric oxide measurements. PBS was obtained from Biochrom AG, 
Germany. 
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2.2 Methods 
2.2.1 Detection of free radicals in the vasculature 
The measurement of vascular free radical production is difficult for 
several reasons. Since radicals are very short lived, they usually do not occur at 
high concentrations in the biological environment. Low intracellular steady-state 
concentrations of superoxide result from the balance between endogenous 
partial reduction of oxygen to superoxide and the scavenging of superoxide by 
highly efficient cytoplasmic and mitochondrial SOD, resulting in intracellular 
superoxide concentrations which rarely exceed 1 nmol/L. Extra cellular release 
of small proportions of intracellularly formed superoxide may occur via anion 
channels. In addition, superoxide levels formed from plasma membrane bound 
oxidases are maintained at low local concentrations due to extra cellular fluid 
components, including low molecular weight oxidant scavengers and the 
heparin binding extracellular (EC)-SOD. Similarly, the intracellular 
concentrations of nitric oxide depend on the balance between the rate of 
formation from L-arginine and the reaction of nitric oxide with superoxide, 
resulting in peroxynitrite formation. Thus, the relatively short half-life (seconds) 
of these radicals and the efficient systems which evolved to scavenge radicals 
require that any detection technique must be sensitive enough to effectively 
compete with these intracellular and extra cellular antioxidant components for 
reaction with the substance in question.  
Some of the currently available methods include chemiluminescence 
techniques, fluorescent based assays, enzymatic assays and electron spin 
resonance. Reduction of ferricytochrome c has been used to measure rates of 
formation of superoxide by numerous enzymes, tissue extracts, and whole cells. 
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The generation of other reactive oxygen intermediates, such as hydrogen 
peroxide or hydroxyl radical can also cause oxidation of ferricytochrome C and 
consequently result in the underestimation of superoxide production187.  
Furthermore, because of its inability to penetrate cells it can be used only to 
measure extra cellular superoxide. Chemiluminescent methods of superoxide 
and nitric oxide detection in vascular tissues have been widely used because of 
the ability of the method to measure intracellular radical production, the alleged 
specificity of the reaction, the minimal cellular toxicity and the purported 
increased sensitivity compared with chemical measurements. However, there is 
uncertainity concerning the precise mechanism of enhanced luminescence-
dependent radical formation, particularly in a cell or tissue based experimental 
system. Therefore, chemiluminescent techniques do not reflect actual cellular 
radical production. 
 
2.2.1.1 Electron spin resonance (ESR) 
The most commonly used methods for evaluation of superoxide and nitric 
production in biological systems are based on reduction of cytochrome C and 
chemiluminescence, respectively. But these techniques have limitations for the 
quantitation of superoxide and nitric oxide due to the fact that cytochrome c and 
luminescent probes can readily react with other products from activated cells188. 
The only analytical approach that permits a highly specific and sensitive direct 
detection of free radicals is ESR, also termed electron paramagnetic resonance 
spectroscopy. 
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2.2.1.2 Principle of ESR 
ESR spectroscopy reports on the magnetic properties of unpaired 
electrons and their molecular environment.  Electrons possess a property called 
spin. The unpaired electrons exist in two orientations, either parallel or 
antiparallel with respect to an applied magnetic field. Electrons in the 
antiparallel state possess higher energy than electrons in the parallel state. 
Resonance is the term used to describe the total energy between the two spin 
states. Paired electrons possess no net spin and hence produce no ESR signal, 
while free radicals which contain one or more unpaired electrons, produce an 
ESR signal. In ESR spectroscopy a fixed frequency of microwave irradiation is 
used to excite the electrons at the lower energy level to the higher energy level.  
An external magnetic field of a specific strength is applied for the transition to 
occur such that the difference in energy levels is matched by the microwave 
frequency.  A unique spectrum is obtained when a spin-trapped free radical is 
exposed to an applied magnetic field (Figure 7). The unpaired electrons which 
produce the ESR spectrum are very sensitive to their surrounding.  
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Figure 7: Principle of ESR spectroscopy. (Picture from Bruker Biospin GmbH, Karlsruhe, 
Germany). 
Free radicals like nitric oxide, superoxide and peroxynitrite are too low in 
concentration and too short lived to be directly detectable by ESR in biological 
systems. This problem can be overcome by the addition of exogenous spin 
traps that react with free radicals to form secondary ESR detectable radicals 
with a higher stability. These spin traps, frequently nitroxide and nitrone 
derivatives, can also be used to label biomolecules and probe basal and 
oxidation induced events in protein and lipid microenvironments. With a 
sensitivity limit of  ~10-9 mol/L, ESR spectroscopy is also capable of detecting 
the more stable free radical species produced in the vascular compartment 
during oxidative stress and inflammation, including ascorbyl radical, 
tocopheroxyl radical, and heme-nitrosyl complexes directly189.  
Reaction of nitric oxide with endogenous heme and non-heme iron 
proteins leads to the formation of iron-nitrosyl complexes with characteristic 
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spectra190. Addition of exogenous iron-dithiocarbamates and nitronyl nitroxides 
has also been used to detect nitric oxide formation191. Endogenous ascorbate is 
oxidized to ascorbate radical which can be directly detected at room 
temperature192. An emerging approach to the use of ESR in vascular biology 
has been the use of cyclic hydroxylamines. These molecules are not spin traps, 
in that they do not “trap” radicals, but they are oxidized to form very stable 
radicals with half-lives of several hours, permitting ESR detection. The spin 
probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine.HCl (CMH) 
is oxidized by superoxide and peroxynitrite to form CM. radical. This molecule 
has successfully been used with intact cells and in vivo to detect reactive 
oxygen species released into the circulation. Thus, the cyclic hydroxylamines 
and similar compounds are very useful for the detection of superoxide and other 
reactive oxygen species in vascular tissues. Overall, ESR has proven to be 
useful as a free radical detection strategy. In this respect superoxide detection 
by ESR was proven to be 20 times more sensitive than the cytochrome C 
reduction assay. 
 
2.2.2 Measurement of vascular nitric oxide production by 
electron paramagnetic spin trapping 
Mice were injected with 100 U of heparin, anaesthetized with Avertin (10 
mg/kg, i.p.) after 5 minutes and dissected on a styrofoam board. The aorta was 
removed rapidly and was cleaned from the perivascular fatty tissues while being 
maintained at 4°C in chilled KHB on a cold plate. The aorta was cut into 2mm 
rings and the rings were placed in each well of a 12 well plate containing 1.5 ml 
KHB. For the preparation of the Fe-(DETC)2 spin trap, 4.5 mg of FeSO4 (1.6 
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mM) and 7.2 mg of DETC (3.2 mM) were prepared separately in 10 ml of 0.9% 
filtered NaCl. The solutions were deoxygenated by bubbling N2 gas for 30 
minutes. Just before use, equal amounts (500 µl) of FeSO4 and DETC solutions 
were mixed quickly in an eppendorf tube pre-filled with N2 gas, to obtain a 
0.8mM of Fe-(DETC)2 colloidal, brown solution. The spin trap (500 µl) was then 
added to the vessels and incubated for 1 hour at 37°C. Subsequently, the 
vessel rings were frozen at the end of the column of KHB buffer in a 1 ml 
syringe. Nitric oxide production was quantitated using an e-scan bench top 
spectroscope with the following instrumental settings: Centre field: 3308 G. 
Sweep width: 80 G. Microwave frequency: 9.495 GHz. Microwave power: 50 
mW. Modulation Amplitude: 4.6 G. Modulation frequency: 86 kHz. Time 
constant: 81.92 ms. Conversion Time: 20.48 ms. Number of scans: 100. The 
method was adapted from a previously published protocol190. The intensity of 
the ESR signal was normalized to the protein content of the sample. 
 
2.2.3 Measurement of vascular oxygen radical production by 
ESR 
ESR measurements of superoxide formation were obtained as the ESR 
detectable nitroxide radical CM. formed through oxidation of the spin probe 
CMH by superoxide and peroxynitrite. The concentrations of reactive oxygen 
species in each sample were calculated from the ESR amplitude using a 
calibration curve of a standard solution of 3-carboxy-proxyl (CP.) radical. In 
order to obtain the maximum signal amplitude, the position of the finger dewar 
was optimized in the cavity using a standard CP.-radical solution. The vessel 
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rings were prepared as mentioned above. The aortas were cut into 2 mm rings 
and five rings were placed in 100 µl KHB containing 25 µM deferoxamine and 5 
µM DETC in each well of a 98 well plate. Deferoxamine and DETC stock 
solutions were prepared by dissolving the compounds in KHB. The reagents 
were freshly prepared everyday. Samples were incubated for 1hour at 37°C 
with the spin probe, CMH (250 µM). Superoxide production was assessed by 
pre incubating aortic rings with PEG-SOD (100 U/ml) parallel to CMH for 1 hour. 
The experimental procedure was carried out according to a previously 
published protocol193. The instrumental settings for superoxide measurements 
are as follows: Centre field: 3388 G. Sweep width: 132 G. Microwave frequency: 
9.497 GHz. Microwave power: 1.25 mW. Modulation Amplitude: 1.63 G. 
Modulation frequency: 86 kHz. Time constant: 40.96 ms. Conversion Time: 
10.24 ms. Number of scans: 50. The intensity of the ESR signal was normalized 
to the protein content of the sample. 
  We chose to use the cyclic hydroxylamine CMH because of its higher 
stability when compared to the widely used nitrone spin traps DMPO and 
DEPMO194. Furthermore, CMH is more sensitive and reliable than the nitrone 
spin traps. In particular CMH has a higher scavenging efficacy for superoxide, 
compared to CP-H, which is another cyclic hydroxylamine.The higher stability of 
CM. even in the presence of reducing agents like ascorbate  or glutathione195 
and the ability of CMH to penetrate cells are additionally advantageous.  
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2.2.3.1 Sample preparation for ESR measurements 
After incubation the vessel rings were frozen at the end of a column of 
KHB solution. In order to do this, the needle-end of a one ml syringe was cut, 
300 µl of KHB were taken up and frozen in liquid nitrogen. Subsequently the 
plunger was retracted an additional 5 mm. A plastic forceps (metal forceps was 
avoided to prevent oxidation caused by metals) were used to collect the rings 
from the 12 well-plate for nitric oxide measurements, without the buffer. Using a 
200 µl Eppendorf tip aortic rings were collected from the 98 well-plate along with 
the buffer containing the spin probe, for superoxide measurements. The rings 
were then layered over the frozen column of KHB in a syringe and were frozen 
in liquid nitrogen again. The syringe plunger was used to push the frozen 
column directly into a liquid nitrogen containing finger dewar vacuum flask. A 
constant supply of dry air was provided to the cavity of the spectrometer to 
avoid condensation. After measurement, the samples were stored in -80°C and 
used for the estimation of the total protein concentration of the vessel rings. 
 
2.2.4 Measurement of nitric oxide bioavailability in the 
bloodstream 
Nitrosyl hemoglobin, a reaction product of deoxygenated hemoglobin 
(Hb) with nitric oxide can be used as a marker for nitric oxide bioavailability196. 
Nitrosyl hemoglobin can be detected as a characteristic triplet peak by ESR 
spectroscopy. Blood samples were prepared according to a published 
method197. Briefly, venous blood was drawn from the right ventricle. Following 
centrifugation at 2000 g the red cell cast was frozen in syringes and transferred 
into a liquid nitrogen containing finger dewar. Spectra were acquired using an 
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X-band EMX spectroscope (Bruker Biospin GmbH, Germany) with the following 
instrument settings: Centre field: 3340 G. Sweep width: 230 G. Microwave 
frequency: 9.452 GHz. Microwave power: 47.6 mW. Modulation Amplitude: 4.76 
G. Modulation frequency: 86 kHz. Time constant: 40.96 ms. Conversion Time: 
10.24 ms. Number of scans: 24. The amount of detected nitric oxide was 
determined from a calibration curve generated by incubating blood samples with 
known concentrations of nitrite and sodium dithionite (Na2S2O4). 
 
2.2.5 Measurement of intracellular superoxide production by 
HPLC detection of oxyethidium 
HPLC measurements served as a second, independent method for 
superoxide detection. Superoxide was measured in aortic rings by detection of 
oxyethidium, the fluorescent reaction product of superoxide and 
dihydroethidium198. Vessel rings were prepared as mentioned before and 
incubated in a 12 well plate, containing KHB and 50 µM dihydroethidium, at 
37°C for 15 minutes. Inhibitors (L-NIO: 100 µM, 1400W: 10 µM, N-AANG: 10 
µM, L-NAME: 100 µM, apocynin: 100 µM) were added and incubated at 37°C 
for 30 minutes, prior to the addition of DHE. Subsequently, extracellular 
dihydroethidium was washed off and the rings were incubated for 1 h for 
intracellular accumulation of oxyethidium. The plate was covered with 
aluminium foil to prevent the exposure of dihydroethidium to light. Aortic rings 
were then homogenized in 350 µl of ice cold methanol. A 50 µl aliquot of the 
homogenate was stored for protein measurements. The homogenate was 
filtered using a syringe top filter (0.2 µm pore size)  and separated by reverse 
phase HPLC using a C-18 column (Nucleosil 250, 4.5 mm; Sigma-Aldrich) 
 - 53 - 
along with an ÄKTA HPLC system (Amersham Biosciences, GE Healthcare). 
The mobile phase was composed of a gradient containing 2.6 column volumes 
of 37- 47% acetonitrile containing 0.1% trifluoroacetic acid. Oxyethidium was 
quantified with a fluorescence detector (Jasco, UK) at 580 nm (emission) and 
480 nm (excitation). The detected oxyethidium was normalised to the sample’s 
protein content 199. 
 
2.2.6 Tissue preparation and immunohistochemistry 
Aortic arches were cleaned of adherent tissue, embedded in Tissue-Tek® 
(Sakura Finetek) and snap-frozen in liquid nitrogen. Serial sections (5 µm) were 
cut at -20°C, mounted on silane treated slides (SuperFrost®Plus, Menzel GmbH 
& Co KG, Braunschweig, Germany), thoroughly air-dried and fixed in acetone 
for 10 minutes at room temperature prior to staining. The slides were allowed to 
dry at room temperature for 1 hour followed by washing thrice with PBS. The 
sections were incubated with 0.3% hydrogen peroxide in methanol for 30 
minutes and washed with PBS. A commercially available blocking reagent 
(Dako REAL, antibody dilutent) was used for 30 minutes and subsequently 
incubated along with the primary anti nitrotyrosine antibody (1:80 dilution, 
Upstate Biotechnology, Inc.) for 1 hour. After washing off unbound antibody, the 
sections were incubated for 30 minutes with the secondary biotinylated anti 
rabbit IgG antibody (1:200 dilution, Vector Laboratories, Inc.) at room 
temperature. Following three PBS washing steps sections were stained for 30 
minutes with ABC reagent (Vectastain®ABC kit, Vector Laboratories, Inc.). 
Sections were then washed with PBS and incubated with DAB reagent for 5-20 
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minutes. At last sections were washed with distilled water and stained with 
Mayer’s Haemalaun stain for 1 minute. 
 
2.2.7 Histomorphometry 
Photomicrographs of the vessel sections were obtained with an Olympus 
camera mounted on a light microscope (Zeiss, Axiophot, Germany). Pictures 
were digitalized with the CellB Imaging software and transferred to a PC for 
planimetry using Image Pro Plus (Media Cybernetics). All images were 
analyzed at 400 fold magnification. Results were expressed as the positive 
staining area per total area of the plaque. 
 
2.2.8 Protein Estimation 
For ESR measurements vessel rings were incubated in 1N NaOH at 
50°C for 2- 3 hours. The protein concentration of the samples was determined 
at 562 nM using a BCA Protein Assay Kit (Pierce,USA). In order to quantify total 
sample protein content, a protein standard curve was generated using bovine 
serum albumin. Samples from vessel homogenates of HPLC samples were 
estimated for their protein content using the BCA Protein Assay Kit in an elisa 
reader (Softmax, Molecular devices).  
 
2.2.9 Statistical Analyses 
The data is represented as mean±SE. Statistical significance was 
determined by Student’s t test for unpaired data. Two groups of data were 
considered to be significantly different at a p value of < 0.05. 
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3.0 Results 
3.1 eNOS is a significant source of vascular wall nitric oxide 
production and circulating nitric oxide 
Quantitation of baseline nitric oxide production in the vasculature is a 
challenging task, due to the radical’s short half-life and very low concentrations 
of bioavailable nitric oxide. We used ESR, a method of highest sensitivity and 
specificity, to measure vascular nitric oxide production and circulating nitric 
oxide levels in blood samples. Spin trapping of nitric oxide with colloidal Fe-
(DETC)2 was used to measure baseline nitric oxide production of the vessel 
wall. This is considered a very specific method for detection of nitric oxide, since 
the Fe-(DETC)2   bound to nitric oxide gives rise to a specific triplet hyperfine 
nitric oxide-Fe-(DETC)2  peak, whereas Fe-(DETC)2 alone does not give any 
signal (Figure 8a). Our experiments show that the baseline nitric oxide 
production of the vessel wall is significantly lower in apoE/eNOS dko (920±287 
AU/µg protein, n=12) than in apoE ko mice (2554±195 AU/µg protein, n=14, 
p<0.0001, Figure 8a and b). In addition, the paramagnetic properties of nitrosyl 
hemoglobin were utilised along with the ESR method to quantify the in vivo 
concentrations of nitric oxide in whole blood196. The baseline nitrosyl 
hemoglobin levels in blood samples were significantly lower in apoE/eNOS dko 
(1868±100 nM, n=11), compared to apoE ko controls (3463±491 nM, n=13, 
p=0.006, Figure 8c). 
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Figure 8. Contribution of vascular and circulating nitric oxide by eNOS: a) Representative 
ESR spectrum of NO-Fe-(DETC)2 in aortic segments of apoE ko and apoE/eNOS dko mice. 
Bold lines indicate apoE ko, stripped lines indicate apoE/eNOS dko, patterned lines indicate 
buffer with spin trap. The arrows show the typical 3 peak signal observed for NO-Fe-(DETC)2, 
which is absent in the buffer only sample. The vertical axis represents signal intensity in 
arbitrary units (AU). b) Aortic nitric oxide production of apoE /eNOS dko mice was reduced by 
60%, compared to apoE ko (*p<0.0001). c) The nitrosyl hemoglobin concentration of blood 
samples from apoE/eNOS dko was reduced by 50%, compared to apoE ko controls (*p=0.006).  
 
 - 58 - 
3.2 eNOS deletion decreases vascular production of superoxide 
in apoE ko vessels 
To determine vascular superoxide production the formation of 
oxyethidium from dihydroethidium was measured by HPLC. The measurements 
revealed higher levels of superoxide in vessel rings of apoE ko and apoE/eNOS 
dko mice, compared to C57Bl6 (9.4±0.5 AU/µg protein, n=14, p=0.000001 and 
6.9±0.9 AU/µg protein, n=13, p=0.04 respectively, vs. 4.4±0.32 AU/µg protein, 
n=9, Figure 9a). Total superoxide formation in apoE/eNOS dko mice was 
decreased compared to apoE ko (6.9±0.9 AU/µg protein vs. 9.4±0.5 AU/µg 
protein, p=0.02, Figure 9a). In addition to the experiments using chronic 
deletion of eNOS, acute pharmacological inhibition of NOS by L-NAME resulted 
in a significant reduction of superoxide formation in apoE ko vessels (9.4±0.5 
AU/µg protein, n=14 vs. 4.8±0.6 AU/µg protein, n=14, p=0.00001, Figure 9b), 
suggesting that NOS is uncoupled and contributes to superoxide formation in 
apoE ko mice. Moreover, L-NIO, an eNOS specific inhibitor significantly 
decreased vascular superoxide production in apoE ko mice fed with the western 
diet for 24 weeks, supporting partial uncoupling of eNOS (9.3±0.6 AU/µg 
protein, n=22 vs. 11.6±0.7 AU/µg protein, n=22, p=0.02, Figure 9c). Superoxide 
levels in these older apoE ko mice were significantly higher than in apoE ko 
mice fed with the western diet for 18 weeks (11.6±0.7 AU/µg protein, n=22, 
p=0.05, Figure 9c) documenting increasing superoxide production with 
progressive atherosclerosis.  
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Figure 9. Determination of eNOS derived superoxide production: a) HPLC measurements 
of superoxide formation showed significantly lower levels of superoxide production in 
apoE/eNOS dko, compared to apoE ko mice following 18 weeks of western diet. Hyperlipidemic 
apoE ko and apoE/eNOS dko mice had significantly higher superoxide levels, compared to 
normocholesterolemic C57Bl6 animals (*p=0.000001; §p=0.02; #p=0.04). b) Unselective NOS 
inhibition by L-NAME resulted in inhibition of superoxide production in apoE ko mice 
(*p=0.00001). c) Vascular superoxide production from 24 weeks western diet fed apoE ko mice 
were significantly elevated, compared to the 18 weeks time point (*p=0.05). Additionally, 
treatment of apoE ko vessel rings with the eNOS specific inhibitor L-NIO decreased vascular 
superoxide formation in 24 weeks western diet fed apoE ko animals ( §p=0.02). 
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3.3 nNOS contributes little to vascular nitric oxide production 
Determination of vascular nitric oxide production using Fe-(DETC)2 
showed no significant difference between apoE ko and apoE/nNOS dko animals 
(2471±189 AU/µg protein, n=16 vs. 2293±124 AU/µg protein, n=17, p=0.43, 
Figure 10). However, a trend towards reduction of vascular nitric oxide 
production (7%) was observed in apoE/nNOS dko animals suggesting that 
nNOS may have a minor contribution. 
 
 
 
Figure 10. Contribution of vascular nitric oxide by nNOS: ESR measurements of vascular 
nitric oxide levels using Fe-(DETC)2 showed no significant difference between apoE ko and 
apoE/nNOS dko animals (NS). 
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3.4 Contribution of nNOS to vascular superoxide production in 
apoE ko animals 
HPLC measurements of intracellular superoxide levels, measured by 
DHE showed no significant difference between apoE ko (19±1.0 AU/µg protein, 
n=12) and apoE/nNOS dko animals (17±1.6 AU/µg protein, n=10, p=0.28, 
Figure 11a), suggesting that chronic nNOS deletion does not alter superoxide 
production in apoE ko animals. However, acute inhibition of nNOS using N-
[(4S)-4-amino-5-[(2-aminoethyl)amino]pentyl]-N'-nitroguanidine tris 
(trifluoroacetate) salt  (N-AANG) showed a significant reduction of superoxide 
formation in apoE ko vessels compared to basal levels (19±1.0 AU/µg protein, 
n=12 vs. 16±1.0 AU/µg protein, n=14, p<0.05, Figure 11b), suggesting that 
vascular nNOS expression contributes to superoxide production. 
 
Figure 11. Determination of nNOS mediated superoxide production: a) HPLC 
measurements of superoxide did not show a significant difference between apoE ko and 
apoE/nNOS dko animals (NS). b) Acute inhibition of nNOS using nNOS specific inhibitor, N-
AANG showed a significant reduction of superoxide production in apoE ko vessels (*p<0.05). 
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3.5 iNOS contributes significantly to vascular nitric oxide 
production 
Detection of vascular wall nitric oxide production using Fe-(DETC)2 spin 
trap showed significantly lower nitric oxide levels in apoE/iNOS dko, compared 
to apoE ko mice (1726±201 AU/µg protein, n=26 vs. 2554±195 AU/µg protein, 
n=14, p≤0.01, Figure 12). Interestingly, nitric oxide production in apoE ko mice 
was increased, compared to C57Bl6 animals (2554±195 AU/µg protein, n=14 
vs. 1453±263 AU/µg protein, n=12, p<0.01, Figure 12).  
 
 
 
 
Figure 12. Contribution of vascular nitric oxide by iNOS: Quantitation of vascular nitric oxide 
levels using Fe-(DETC)2 spin trap. While apoE ko vessels showed higher levels of nitric oxide 
formation compared to C57Bl6 animals (**p<0.01), there was no statistical difference between 
C57Bl6 and apoE/iNOS dko animals. 
 
Genetic deletion of iNOS in apoE ko reduced nitric oxide 
formation significantly (*p≤0.01).  
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3.6 iNOS plays a major role in vascular superoxide production 
ESR measurements of SOD inhibitable superoxide levels showed that 
apoE ko aortas produce significantly higher superoxide levels than apoE/iNOS 
dko vessels (10.8±0.8 nM/µg protein, n=18 vs. 7.5±0.8 nM/µg protein, n=20, 
p≤0.01, Figure 13a). Additionally, superoxide was measured by HPLC 
quantification of oxyethidium, the specific reaction product of dihydroethidium 
and superoxide. In support of the ESR data, the HPLC assay showed that apoE 
ko vessels produce higher superoxide levels compared to apoE/iNOS dko mice 
(8.9±0.6 AU/µg protein, n=15 vs. 5.7±0.8 AU/µg protein, n=16, p≤0.01, Figure 
13b). Superoxide levels of C57Bl6 animals (4.5±0.3 AU/µg protein, n=9, 
p<0.0001, Figure 13b) were significantly lower than the concentrations 
observed in apoE ko mice. The levels of superoxide in apoE/iNOS dko and 
C57Bl6 animals were comparable. In other words, absence of iNOS reduced 
superoxide production in apoE ko almost to the level of C57Bl6 animals. To 
determine whether acute pharmacologic inhibition of iNOS reproduces these 
results, we incubated apoE ko aortas with the iNOS specific inhibitor N-(3-
aminomethyl) benzyl-acetamidine (1400W). Acute iNOS inhibition significantly 
reduced superoxide levels in apoE ko vessels, compared to basal levels 
(4.2±0.8 AU/µg protein, n=10 vs. 8.9±0.6 AU/µg protein, n=15, p≤0.0001, Figure 
13c). Our results suggest that uncoupled iNOS itself is a significant source of 
superoxide formation in apoE ko vessels.  
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Figure 13. Determination of iNOS derived superoxide production: a) Superoxide levels 
were significantly lower in apoE/iNOS dko animals, compared to apoE ko controls (ESR 
measurements of SOD inhibitable CM. signal (**p≤0.01)). b) Additionally, HPLC measurements 
revealed that iNOS deletion reduced vascular superoxide production in apoE ko animals. ApoE 
ko had significantly higher vascular superoxide levels than C57Bl6 animals (*p≤0.01, 
**p≤0.0001). c) Acute inhibition of iNOS in vessels of apoE ko mice, using iNOS specific inhibitor 
1400W, significantly reduced superoxide production (§p≤0.0001). 
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3.7 Nitric oxide and superoxide generation from iNOS results in 
peroxynitrite formation 
Peroxynitrite, a reaction product of nitric oxide and superoxide was 
quantified by measuring 3-nitrotyrosine positive atherosclerotic plaque areas 
(Figure 14a). Peroxynitrite staining was significantly reduced in apoE/iNOS dko, 
compared to apoE ko animals (0.4±0.1 positive staining area/total area, n=8 vs. 
1.5±0.3 positive staining area/total area, n=8, p<0.05, Figure 14a and b).  
 
Figure 14. Quantification of peroxynitrite mediated nitrosative stress: a) Representative 
immunohistochemistry of 3-nitrotyrosine staining, a marker of peroxynitrite mediated oxidative 
stress in aortic plaques of apoE ko and apoE/iNOS dko animals. b) Planimetry of % positive 
staining plaque areas for 3-nitrotyrosine revealed decreased nitrosative stress in lesion of 
apoE/iNOS dko, compared to apoE ko animals (*p<0.05). 
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3.8 iNOS deletion influences NADPH oxidase mediated 
superoxide production 
Since iNOS expression may regulate NADPH oxidase activity and 
expression we determined the contribution of NADPH oxidase to superoxide 
formation in apoE ko vessels. Our results show that apocynin, a NADPH 
oxidase inhibitor significantly reduced superoxide levels compared to basal 
superoxide production of apoE ko vessels (13±0.6 AU/µg protein, (n=13) vs. 
19±1.0 AU/µg protein, (n=12), p<0.001, Figure 15). In contrast, we observed no 
difference in superoxide levels between basal and apocynin treated apoE/iNOS 
dko vessels (14±1.5 AU/µg protein, (n=11) vs. 13±1.2 AU/µg protein, (n=12), 
p=0.46, Figure 15). Therefore, our results suggest that iNOS deletion reduces 
the activity of the NADPH oxidase.  
 
 
 
Figure 15. Influence of iNOS in NADPH oxidase activity: Treatment of vessel rings with the 
NADPH oxidase inhibitor, apocynin resulted in a significant reduction of superoxide production 
in apoE ko vessels (**p<0.001). As shown before, genetic deletion of iNOS resulted in 
significant reduction of superoxide (*p<0.05). Apocynin treatment showed a trend towards 
reduction of superoxide production in apoE/iNOS dko animals (NS). 
 - 67 - 
 
 
 
 
 
 
     
 
Chapter 4 
 
 
 
 
 
 
 
 
 
 
 - 68 - 
4.0 Discussion 
 
4.1 eNOS is a major contributor of nitric oxide and superoxide 
generation in apoE ko vessels 
We have previously shown that eNOS protects from atherosclerosis, as 
genetic deletion of eNOS resulted in increased plaque formation in apoE ko 
mice. Further, we also observed increased leukocyte/endothelial cell 
interactions, increased macrophage infiltration and increased expression of 
vascular cell adhesion molecule (VCAM-1) in apoE/eNOS dko animals 
compared to apoE ko controls (data not shown/ unpublished data). Considering 
the expression of all three NOS isoforms in the atherosclerotic plaques, nitric 
oxide production by the vessel wall could be decreased secondary to eNOS 
deletion or increased since the increase in leukocyte/endothelial interactions, 
macrophage infiltration and plaque area observed in apoE/eNOS dko could 
increase cytotoxic nitric oxide formation by iNOS. Moreover, eNOS deletion 
could have changed the bioavailability of substrate and co-factor, thereby 
influencing the chemistry of iNOS and nNOS. Considering the alternative 
chemistry of eNOS, deletion of the enzyme could also reduce superoxide 
production and thereby indirectly increase nitric oxide bioavailability by nNOS 
and iNOS. Because of this alternative chemistry of eNOS, we measured both 
vascular nitric oxide and superoxide formation in aortic segments of apoE ko 
and apoE/eNOS dko mice using ESR and HPLC methods. Spin trapping of 
nitric oxide using Fe-(DETC)2 is considered the utmost specific and sensitive 
method for detection of nitric oxide in biological systems. Unlike 
chemiluminescence, a frequently used method which indirectly measures nitric 
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oxide’s metabolite nitrite, ESR directly detects nitric oxide as a specific
 
hyperfine 
triplet peak190. Our experiments show a significant reduction of baseline nitric 
oxide formation in the vessel wall of apoE/eNOS dko, compared to apoE ko 
mice. In addition, the in vivo concentration of circulating nitrosyl hemoglobin, a 
measure for nitric oxide bioavailability in the circulation, was markedly reduced 
in apoE/eNOS dko mice. Our data suggest that eNOS is the major contributor of 
vascular and circulating nitric oxide despite all these possibilities. Since eNOS 
is expressed in the endothelium lining the lumen of the vessel, the nitric oxide 
generated by eNOS can easily diffuse into the circulation, explaining the 
significant contribution of eNOS to circulating levels of nitric oxide. 
To assess vascular superoxide formation we used a HPLC assay which 
measures the formation of oxyethidium, a specific reaction product of 
dihydroethidium with superoxide199. These measurements revealed a significant 
reduction in superoxide production following genetic deletion of the enzyme 
(chronic) in apoE/eNOS dko, and acute pharmacological inhibition of eNOS in 
apoE ko. The reduction of superoxide generation observed in apoE/eNOS dko 
reflects the specific contribution of eNOS derived superoxide production in 
endothelial cells. Since both, significant nitric oxide and superoxide production 
by eNOS is detectable in apoE ko mice, we conclude that eNOS is partially 
uncoupled during atherosclerosis development in this model. We speculate that 
eNOS produces nitric oxide in the healthy regions of the vessel, whereas in the 
diseased regions, it is uncoupled and contributes to superoxide production.  
As recently shown in eNOS transgenic apoE ko mice, reduced nitric 
oxide and increased superoxide generation by uncoupled eNOS can accelerate 
atherosclerosis151. However, despite decreased vascular superoxide formation 
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in our apoE/eNOS dko model, these animals develop increased atherosclerosis, 
suggesting that the atheroprotective effect of decreased superoxide production 
does not outweigh the proatherogenic effects of nitric oxide deficiency. Ample 
evidence implicates increased superoxide production in atherosclerosis43, 70. 
Our data is consistent with this hypothesis since we observed increased 
superoxide production in apoE ko and apoE/eNOS dko compared to C57Bl6 
animals. In fact our results suggests that uncoupled eNOS is a significant 
source of superoxide production in apoE ko. It appears that the decrease in 
superoxide production from eNOS is not able to counterbalance the 
proatherogenic effects that resulted from the inhibition of eNOS dependant nitric 
oxide production.  
 
4.2 Vascular nNOS generates low amounts of nitric oxide and 
superoxide  
We had previously shown that nNOS has an anti atherogenic role, as 
genetic deletion of nNOS resulted in accelerated atherosclerosis in apoE ko 
mice165. Since nNOS is expressed in endothelial cell, smooth muscle cells and 
macrophages164 we determined to estimate the contribution by nNOS to total 
vascular nitric oxide production in atherosclerosis. Our ESR experiments show 
that nNOS only contributes little to total vascular nitric oxide production (7% 
reduction of total nitric oxide production, p>0.05). However, atheroprotection by 
nNOS may be mediated through several direct or indirect mechanisms. nNOS is 
expressed outside the cardiovascular system, for example in nerves innervating 
endocrine organs such as pituitary and adrenal medulla104 and hence may 
regulate hormones which potentially modulate atherosclerosis development. 
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Further, since nNOS is expressed in smooth muscle cells and macrophages of 
the atherosclerotic plaques164, 165 nitric oxide generated by nNOS may directly 
inhibit smooth muscle cell proliferation. And indeed, we observed increased 
smooth muscle cell proliferation in apoE/nNOS dko animals.  Within the smooth 
muscle cells and macrophages nNOS can potentially co-localize with other PDZ 
domain containing proteins which in turn might target nNOS towards 
intracellular components which regulate migration and proliferation. 
Furthermore, it is plausible that nNOS might decrease leukocyte and platelet 
adhesion to the endothelium when localized toward the vessel lumen, whereas 
nNOS localized toward the adventitia might inhibit smooth muscle cell 
proliferation. In the small intestine of rats nNOS negatively regulates the 
expression of iNOS200.  However, this regulation does not seem to occur in 
apoE ko mice, since we observed equal amounts of iNOS expression in apoE 
ko and apoE/nNOS dko animals165.  
  Studies in nNOS ko mice have shown that deficiency of nNOS resulted in 
increased xanthine oxidase mediated superoxide formation201 suggesting that 
nNOS mediated nitric oxide decreases superoxide production. In order to check 
the influence of nNOS on superoxide production in apoE ko vessels, we 
performed HPLC measurements of superoxide. Our results show that genetic 
deletion of nNOS did not alter vascular superoxide levels as the enzyme 
produces only low levels of nitric oxide. However, acute pharmacological 
inhibition of nNOS resulted in a significant reduction in superoxide formation, 
suggesting that nNOS might be uncoupled in atherosclerosis.  Our data raises 
the possibility, that chronic nNOS deletion initiates compensatory mechanisms, 
like increased SOD or glutathione activity. In vitro studies have shown that 
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under conditions of substrate or co-factor deficiency, nNOS uncouples to 
generate superoxide117, 121. It was recently shown that induced expression of 
nNOS in neuroepithelial cells202 and over expression of nNOS in neuroblastoma 
cells resulted in increased nNOS mediated superoxide formation203. These 
results are consistent with our observation in atherosclerotic vessel where the 
expression of nNOS is induced during atherosclerosis164.  
 
4.3 iNOS generates nitric oxide and superoxide simultaneously 
in apoE ko vessels 
Our ESR measurements show that iNOS significantly contributes to nitric 
oxide production in the vasculature of atherosclerotic apoE ko mice. 
Interestingly, total aortic nitric oxide formation is increased in apoE ko, 
compared to healthy wild type C57Bl6 mice. Vascular nitric oxide production in 
apoE/iNOS dko mice was reduced to the levels of C57Bl6 mice, suggesting that 
the source of increased nitric oxide production in apoE ko mice is iNOS. Since 
iNOS is expressed in smooth muscle cells and leukocytes in the plaque, these 
cell types mediate the additional aortic nitric oxide production164. iNOS is 
regulated transcriptionally and catalyses the production of high concentrations 
of nitric oxide, once the enzyme is expressed. In contrast, eNOS and nNOS 
produce low amounts of nitric oxide in a highly regulated way.  
Indirect measurements of nitric oxide like the L-arginine to L-citrulline 
conversion assay and cGMP levels suggest that  there is  reduced eNOS 
activity in atherosclerotic vessels67. The impaired endothelial nitric oxide 
production results in impaired endothelial vasodilator function also termed 
endothelial dysfunction. Therefore, atherosclerosis is generally considered a 
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state of decreased nitric oxide bioavailability. In contrast, our data shows that 
iNOS increases total nitric oxide production of the vessel wall in the apoE ko 
model. Since iNOS activity is not regulated by calcium influx, the iNOS 
mediated nitric oxide production does not locally mediate endothelium derived 
vasorelaxation. Instead, the iNOS mediated increased nitric oxide production 
observed during bacterial sepsis can result in life threatening hypotension due 
to systemic vasorelaxation204. Our study is consistent with the previously 
published report by Minor et al., who showed increased nitrogen oxides in the 
aorta of atherosclerotic rabbits205. This study employed an indirect method for 
nitric oxide detection and didn’t specify the source of nitric oxide production. 
Thus, the induction of iNOS expression in atherosclerosis results in increased 
vascular nitric oxide production, compared to wild type mice.  
Increased superoxide production can decrease nitric oxide bioavailability 
and result in proatherogenic oxidative stress. Aside from other enzymatic 
sources of superoxide, iNOS itself may contribute directly to superoxide 
production. Therefore, we evaluated superoxide production in apoE ko and 
apoE/iNOS dko mice. Employing two independent direct methods, we found a 
significant decrease in vascular wall superoxide production in apoE/iNOS dko, 
compared to apoE ko.  In addition, total vascular reactive oxygen species (ROS) 
production, assessed by measuring the conversion of CMH to nitroxide CM.
 
was significantly reduced in apoE/iNOS dko, compared to apoE ko animals 
(data not shown). Since decreased oxidative stress in chronically iNOS deficient 
mice could also result from secondary changes, i.e. iNOS mediated regulation 
of gene expression; we tested whether acute pharmacological iNOS inhibition 
reduces vascular superoxide production. And indeed, pretreatment of the 
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vessels with the iNOS specific inhibitor 1400W significantly reduced superoxide 
levels, indicating that iNOS itself contributes to superoxide production in 
atherosclerosis. To the best of our knowledge this is the first evidence 
supporting superoxide generation by iNOS in atherosclerosis. In contrast, ample 
evidence supports eNOS “uncoupling” and subsequent superoxide, instead of 
nitric oxide production151, 206. The mechanism of superoxide generation by iNOS 
differs from eNOS and nNOS. The latter two enzymes produce superoxide from 
the heme centers of their oxygenase domains35, 117, while iNOS produces 
superoxide from the reductase domain136. While 100 µM of L-arginine was 
sufficient to block superoxide generation from nNOS117, there was no effect of 
100 µM L-arginine on iNOS mediated superoxide generation136. Higher 
concentrations of L-arginine (1mM–5mM) only reduced, but did not abolish 
superoxide production, indicating that superoxide generation by iNOS may even 
occur when substrate is not limited136. Xia et al. reported that induction of iNOS 
in macrophages reduced L-arginine concentrations, indicating high substrate 
demand37. These authors hypothesized that iNOS may catalyze nitric oxide 
from the oxygenase- and superoxide from the reductase domain 
simultaneously, which could directly lead to peroxynitrite formation.  
Quantification of tissue 3-nitrotyrosine, considered a footprint of 
peroxynitrite mediated protein damage showed reduced levels of 3-nitrotyrosine 
in apoE/iNOS dko vessels, compared to apoE ko vessels. Peroxynitrite oxidizes 
BH4, a cofactor of NOS207 which in its oxidized form causes uncoupling of the 
constitutive NOS enzymes103. Further, peroxynitrite can directly cause 
irreversible uncoupling and inactivation of nNOS208. iNOS mediated 
peroxynitrite formation and its high substrate demand may thus cause 
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uncoupling of constitutive NOS isoforms, resulting in further superoxide 
production. The residual peroxynitrite detected in apoE/iNOS dko might be due 
to the reaction of nitric oxide from constitutive NOS with superoxide generated 
from myeloperoxidase, NADPH oxidase and xanthine oxidase. 
iNOS and NADPH oxidase are pro inflammatory enzymes and known to 
be expressed in atherosclerotic vessels43, 164 and the expression of both 
enzymes coincides with localized oxidative stress in the lesions. NADPH 
oxidase is proposed to negatively regulate the expression of iNOS in smooth 
muscle cells209. While increased nitric oxide generated by iNOS is suppresses 
the expression and activity of NADPH oxidase under certain inflammatory 
conditions210 interleukin-1 induced nitric oxide (i.e iNOS) increases NADPH 
oxidase activity in smooth muscle cells of coronary arteries211. Since complex 
interactions exists between iNOS and NADPH oxidase we determined the 
contribution of NADPH oxidase to superoxide production in apoE ko and 
apoE/iNOS dko atherosclerosis. Consistent with the previous observation that 
NADPH oxidase is one of the major sources of superoxide generation in 
atherosclerosis44, we found that NADPH oxidase significantly contributes to 
superoxide production in atherosclerosis. The reduction of superoxide 
production mediated by the NADPH oxidase inhibitor apocynin was similar to 
that observed in apoE/iNOS dko animals and inhibition of NADPH oxidase by 
apocynin did not further reduce the superoxide levels in apoE/iNOS dko 
vessels. These results suggest that the decrease of superoxide production 
observed in apoE/iNOS dko aorta is largely due to decreased NADPH oxidase 
activity in this genotype.  
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Summary and Hypothesis 
The principle product of each NOS is nitric oxide. However, under 
conditions of substrate and cofactor deficiency the enzymes directly catalyze 
superoxide formation. Considering this alternative chemistry of each NOS, the 
effects of each single enzyme on key events of atherosclerosis are difficult to 
predict. Here, we evaluate nitric oxide and superoxide production by all three 
NOS isoforms in atherosclerosis.  
ESR measurements of circulating and vascular wall nitric oxide 
production showed significantly reduced nitric oxide levels in apoE/eNOS 
double knockout (dko) and apoE/iNOS dko animals but not in apoE/nNOS dko 
animals suggesting that eNOS and iNOS majorly contribute to vascular nitric 
oxide production in atherosclerosis. Pharmacological inhibition and genetic 
deletion of eNOS and iNOS reduced vascular superoxide production suggesting 
that eNOS and iNOS are uncoupled in atherosclerotic vessels. Though genetic 
deletion of nNOS did not alter superoxide production, acute inhibition of nNOS 
showed that nNOS contributes significantly to superoxide production.  
In conclusion, uncoupling of eNOS occurs in apoE ko atherosclerosis but 
eNOS mediated superoxide production does not outweigh the protective effects 
of eNOS mediated nitric oxide production. We show that although nNOS is not 
a major contributor of the vascular nitric oxide formation, it prevents 
atherosclerosis development. Acute inhibition of nNOS showed a significant 
reduction of superoxide formation suggesting that nNOS is uncoupled. The 
exact mechanism of action of nNOS in atheroprotection is yet to be elucidated.   
Genetic deletion of iNOS reduced NADPH oxidase activity. Thus, iNOS has 
both direct and indirect proatherosclerotic effects, as it directly generates both 
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nitric oxide and superoxide simultaneously resulting in peroxynitrite formation 
and indirectly modulates NADPH oxidase activity. 
We hypothesize that eNOS is coupled in the disease free regions of the 
vessel and contributes to nitric oxide generation whereas in the diseased region 
of the vessel it is uncoupled to produce superoxide (Figure 16). nNOS 
expressed in the smooth muscle cells of the plaque contributes to the local 
superoxide generation. iNOS expressed in smooth muscle cells and leukocytes 
of the plaque generates superoxide and nitric oxide simultaneously to produce 
the strong oxidant peroxynitrite. 
 
 
Figure 16. Proposed hypothesis. 
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Zusammenfassung und Hypothese 
Stickstoffmonoxid (NO) ist das prinzipielle Produkt aller 
Stickstoffmonoxid-Synthasen (NOS). Im Falle eines Mangels an Substrat (L-
arginin) und Kofaktoren (Tetrahydrobiopterin, BH4) katalysieren die NOS-
Enzyme direkt Superoxid (O2-). Diese Veränderung in der Radikalproduktion 
wird auch als Entkopplung der NOS bezeichnet. Die alternative Produktion von 
NO oder O2- durch die NOS bedingen, dass eine Voraussage über die 
Schlüsselfunktion der einzelnen Enzyme in der Entstehung der Atherosklerose 
schwierig ist. In unserer Studie evaluieren wir die Produktion von NO sowie O2- 
in atherosklerotischen Läsionen von apoE ko Mäusen und apoE/NOS doppel 
knockout (dko) Mäusen denen jeweils eine NOS-Isoform fehlt. 
Elektronen Spin Resonanz (ESR) Messungen konnten eine signifikante 
Reduktion sowohl des zirkulierenden, als auch der Gefäßwand eigenen 
Produktion von NO in apoE/eNOS dko und apoE/iNOS dko Mäusen zeigen, 
nicht jedoch in apoE/nNOS dko Mäusen. Dies lässt darauf schließen, dass 
eNOS und iNOS den hauptsächlichen Anteil der vaskulären NO-Produktion in 
atherosklerotischen Läsionen bewerkstelligen. 
Die pharmakologische Inhibierung wie auch die genetische Deletion von 
eNOS und iNOS führten ebenfalls zu einer reduzierten vaskulären O2- 
produktion, was die partielle Entkopplung beider Enzyme in atherosklerotisch 
veränderten Gefäßen nahe legt. Obwohl die chronische genetische Deletion 
von nNOS in apoE/nNOS dko die O2- Produktion nicht verändert, zeigte sich bei 
der akuten pharmakologischen Inhibierung von nNOS (durch L-NAANG) eine 
maßgebliche Beteiligung von nNOS an der O2- produktion in apoE ko Mäusen. 
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Schlussfolgernd lässt sich sagen, dass in atherosklerotischen Gefäßen 
von apoE ko Tieren eine Entkopplung von eNOS statt findet, diese jedoch zu 
keinem Ausgleich der protektiven Effekte der eNOS vermittelten NO-Produktion 
führt. Unsere Ergebnisse in apoE/nNOS dko Mäusen zeigen eine 
atheroprotektive Rolle der nNOS, die sich nicht allein durch eine lokale, 
vaskuläre NO-Produktion durch das Enzym erklären lässt. Wir postulieren 
weitere systemisch atheroprotektive Eigenschaften der nNOS. Die signifikante 
Reduktion der Superoxidproduktion durch eine akute Inhibierung der nNOS 
weist auf eine Entkopplung der nNOS hin. Der exakte Wirkungsmechansimus 
von nNOS in der Atheroskleroseprävention ist weiterhin noch zu eruieren. Die 
genetische Deletion von iNOS führt zu einer reduzierten Aktivität der NADPH-
Oxidase. Demnach sind für iNOS direkte sowie indirekte 
atherosklerosefördernde Effekte anzunehmen, da sie auf direktem Wege 
gleichzeitig NO und O2- produziert, was in einer Peroxynitritbildung resultiert. 
Wir stellen die Hypothese auf, dass eNOS in den läsionsfreien 
Gefäßregionen gekoppelt ist und dort seine atheroprotektiven Effekte durch die 
NO-Produktion vermittelt, während die eNOS in atherosklerotischen Läsionen 
entkoppelt vorliegt und hier O2- produziert (Fig. 16). iNOS, welches vor allem in 
den Plaques, in glatten Muskelzellen und Leukozyten zu finden ist, produziert 
gleichzeitig hohe Konzentrationen von O2- und NO, die als gemeinsames 
Endprodukt das stark oxidierende Peroxynitrit ergeben und die von uns 
dokumentierte proatherosklerotische Wirkung der iNOS vermittelt. 
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Apo E  : Apolipoprotein E 
BH4  : Tetrahydrobiopterin 
CAD  : Coronary artery disease 
DETC  : Diethyldithiocarbamic acid  
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KHB  : Krebs Hepes Buffer 
L-NAME : L-arginine methyl ester 
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HPLC  : High Performance Liquid Chromatography 
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Ox-LDL : Oxidized LDL 
TNF-α  : Tumor necrosis factor- α 
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Thesaurus 
 
Definitions 
 
• Allograft / vein graft arteriosclerosis refers to arteriosclerosis developed 
following tissue or vein graft transplantation. An allograft or homograft is a 
transplant in which transplanted cells, tissues, or organs are sourced from a 
genetically non-identical member of the same species. Most human tissue and 
organ transplants are allografts. 
 
• Angina pectoris, commonly known as angina, is chest pain due to ischemia  of 
the heart muscle, generally due to obstruction or spasm of the coronary arteries 
(the heart's blood vessels). Coronary artery disease, the main cause of angina, is 
due to atherosclerosis of the cardiac arteries. 
 
• Aortic aneurysm is a general term for any swelling of the aorta, usually 
representing an underlying weakness in the wall of the aorta. While the stretched 
vessel may occasionally cause discomfort, a greater concern is the risk of 
rupture which causes severe pain; massive internal bleeding and without prompt 
treatment results in quick death.  
 
• Aortic dissection is a tear in the wall of the aorta that causes blood to flow 
between the layers of the wall of the aorta and force the layers apart. Aortic 
dissection is a medical emergency and can quickly lead to death, even with 
optimal treatment. 
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• Balloon angioplasty is a widely used catheter-based technique for opening 
blocked arteries and treating coronary artery disease (CAD) and is one of the 
standard treatments for CAD. To restore normal blood flow, a balloon-tipped 
catheter is guided into one of the clogged arteries, and the balloon is rapidly 
inflated. This action helps blood flow more freely through the vessel by pushing 
the plaque back against the artery wall, creating small cracks or fissures called 
plaque fractures within the brittle, fatty deposit and by stretching the artery. 
 
• Cardiac hypertrophy is a thickening of the heart muscle (myocardium) which 
results in a decrease in size of the chamber of the heart, including the left and 
right ventricles. 
 
• Cardiomyopathy is the deterioration of the function of the myocardium (i.e., 
the heart muscle) for any reason. People with cardiomyopathy are often at risk of 
sudden cardiac death.  
 
• Carotid artery ligation model is an animal model that is used to study arterial 
injuries. The carotid artery is ligated using a wire, to cause denudation of the 
endothelium, representing vascular injury during angioplasty. 
 
• Caveolae (Latin for little caves) are small (50–100 nanometer) invaginations of 
the plasma membrane in many vertebrate cell types, especially in endothelial 
cells and adipocytes. 
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• Claudication refers to leg pain brought on by exertion and relieved with rest. 
Claudication is also known as intermittent claudication, peripheral vascular 
disease, or "poor circulation." The primary cause of claudication is 
atherosclerosis, or narrowing of the arteries that feed the leg muscles. 
 
• Congestive heart failure or heart failure is a condition in which the heart can't 
pump enough blood to the body's other organs. 
 
• Coronary artery disease (CAD)- a disease in which the blood flow to the heart 
is restricted due to hardened arteries (atherosclerosis) that are clogged with 
plaque deposits. 
 
• Endothelial dysfunction is the physiological dysfunction of normal 
biochemical processes carried out by the endothelium. 
 
• Hypercholesterolemia is the presence of high levels of cholesterol in the blood. 
It is not a disease but a metabolic derangement that can be secondary to many 
diseases and can contribute to many forms of cardiovascular disease. 
 
• Hyperplasia is a general term referring to the proliferation of cells within an 
organ or tissue beyond that which is ordinarily seen in constantly dividing cells. 
Hyperplasia may result in the gross enlargement of an organ, the formation of a 
benign tumor, or may be visible only under a microscope.  
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• Ischemia is a restriction in blood supply, generally due to factors in the blood 
vessels, with resultant damage or dysfunction of tissue. 
 
• L type calcium channels are a type of voltage-dependent calcium channel. 
Voltage-dependent calcium channels are a group of voltage-gated ion channels 
found in excitable cells (e.g., muscle, glial cells, neurons, etc.) with a 
permeability to the ion Ca2+. At physiologic or resting membrane potential, 
voltage-dependent calcium channels are normally closed. They are activated 
(i.e., opened) at depolarized membrane potentials and this is the source of the 
"voltage-dependent" epithet. Activation of particular voltage-dependent calcium 
channels allows Ca2+ entry into the cell, which depending on the cell type, 
results in muscular contraction, excitation of neurons, up-regulation of gene 
expression, or release of hormones or neurotransmitters. 
 
• Myocardial infarction more commonly known as a heart attack is a medical 
condition that occurs when the blood supply to a part of the heart is interrupted, 
most commonly due to rupture of a vulnerable plaque. 
 
• Myocardial ischemia is a condition in which oxygen deprivation to the heart 
muscle is accompanied by inadequate removal of metabolites because of 
reduced blood flow or perfusion. 
 
• Neuroblastoma is the most common extracranial solid cancer in childhood and 
the most common cancer in infancy, with an annual incidence of about 650 new 
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cases per year in the US. It is a neuroendocrine tumor, arising from any neural 
crest element of the sympathetic nervous system. 
 
• Nitrergic nerves: Nerve where transmission is mediated by nitric oxide. 
 
• Non-adrenergic non-cholinergic  neuron usually refers to autonomic efferent 
neuron whose transmission is not blocked by blocking adrenergic 
(catecholamines) and cholinergic (acetylcholine) transmission. Nitric oxide may 
be the transmitter in some cases.  
 
• Protein kinase G (PKG) is a serine/threonine-specific protein kinase that is 
activated by cGMP. It phosphorylates a number of biologically important targets 
and is implicated in the regulation of smooth muscle relaxation, platelet 
function, sperm metabolism, cell division and nucleic acid synthesis. 
 
• Reperfusion injury refers to damage to tissue caused when blood supply 
returns to the tissue after a period of ischemia. The absence of oxygen and 
nutrients from blood creates a condition in which the restoration of circulation 
results in inflammation and oxidative damage through the induction of oxidative 
stress rather than restoration of normal function. 
 
• Restenosis literally means the reoccurrence of stenosis. This is usually 
restenosis of an artery, or other blood vessel that has been "unblocked" by 
mechanically widening a narrowed or totally obstructed blood vessel (as a result 
of atherosclerosis) using interventional techniques like angioplasty. 
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• Sepsis is a serious medical condition characterized by a whole-body 
inflammatory state caused by infection. Sepsis is broadly defined as the presence 
of various pus-forming and other pathogenic organisms, or their toxins, in the 
blood or tissues. 
 
• Soluble guanylate cyclase (sGC, (EC 4.6.1.2), also known as guanylyl cyclase 
or GC) is a lyase enzyme. It catalyzes the conversion of guanosine triphosphate 
(GTP) to 3',5'-cyclic guanosine monophosphate (cGMP) and pyrophosphate. 
sGC is a receptor for NO (thus also called NO receptor). It is soluble i.e. 
completely intracellular. It is most notably involved in vasodilation. 
 
• Transplant arteriosclerosis develops following organ transplantation. 
 
• Vasodilator is a drug or chemical that relaxes the smooth muscle in blood 
vessels, which causes them to dilate.  
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